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Effect of prolonged ascorbic acid deprivation 
on collagen formation. 
It has been recognised for many years that a failure to form 
collagen is one of the characteristic features of prolonged ascorbic 
acid deprivation. As early as 1753 Lind, in his "Treatise of the 
Scurvy ", recorded the observation that one of the symptoms of scurvy 
was that wounds failed to heal. He noted also that a "peculiar 
laxness" of the tissues was found at autopsy - a condition now 
known to be due to the failure in collagen formation. Wolbach 
and his associates, from histological studies in guinea -pigs which 
had been rendered scorbutic, concluded that the primary defect in 
scurvy was a failure of the fibroblasts to form collagen ( Wolbach 
and Howe, 1926; Wolbach, 1933; Boyle, Bessey and Wolbach, 1937). 
The addition of orange juice to the diet of the experimental 
animals caused a prompt resumption of collagen formation. 
Hunt (1941) observed that collagen does not form in experimental 
wounds produced in guinea -pigs which have suffered prolonged vitamin C 
deprivation and that the intercellular material remains immature. 
Collagen of normally- healing wounds reverts to pre- collagen when 
scurvy intervenes. Penny and Balfour (1949) observed in healing 
wounds in scorbutic guinea -pigs that some fibroblastic proliferation 
occurs but the fibroblasts do not form syncytia and there is very 
little extra -cellular material. If ascorbic acid is given normal 
fibroblasts appear and fine reticular fibres and much extracellular 
material is found. Crandon and Lund (1940), however, found that 
in a human subject, after 4 months on a vitamin C -free diet, an 
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experimental wound healed normally even though the plasma, 
leucocyte and platelet ascorbic acid had fallen to zero. After 
a longer period of deprivation there was failure to heal in an 
experimental wound and microscopic examination showed a lack of 
intercellular material. Parenteral administration of ascorbic 
acid caused healing to commence and considerable intercellular 
material appeared in 10 days. 
The part played by ascorbic acid in collagen formation is 
still unknown although Penney and Balfour (1949) observed that 
an acid mucopolysaccharide was produced in healing wounds in 
guinea -pigs but that this acid mucopolysaccharide was not 
produced in scorbutic animals. This mucopolysaccharide is 
possibly hyaluronic acid which is a component of connective tissue. 
Elster (1950) investigated the collagen content of the tissues of 
ascorbic acid depleted guinea -pigs and found no difference in 
collagen content between these animals and weight controls. He 
concluded that ascorbic acid is not necessary for maintaining 
collagen once formed but is possibly necessary for replacement of 
loss. If this view is correct it could explain the long time 
necessary for failure of wound -healing to develop in Crandon's 
human subject. Burns, Burch, and King (1951) fed 1 -C14-L- 
ascorbic acid to guinea -pigs and could detect no radio -activity 
in chondroitin sulphate or collagen isolated from skin and 
cartilage. It would appear, therefore, that ascorbic acid does 
not serve as a precursor or a component of collagen. 
A possible explanation of the failure of collagen -formation 
in the scorbutic state is provided by the effect of ascorbic acid 
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deficiency on the metabolism of phenylalanine and tyrosine. In 
the inborn error of metabolism known as alcaptonuria homogentisic 
acid - 2:5 dihydioxyphenylacetic acid - appears in the urine, 
although it is not a normal constituent of urine, and the amount 
of homogentisic acid excreted increases if either phenylalanine or 
tyrosine is fed to the patient. It would appear therefore that 
homogentisic acid is an intermediate substance in the metabolism 
of phenylalanine and tyrosine and that the defect in the alcaptonuric 
subject is that this metabolite is not oxidised further. 
Sealock and Silberstein (1940) observed that scorbutic guinea- 
pigs excreted p- hydroxyphenyl compounds in the urine and Levine, 
Gordon and Marples (1911) found p- hydroxyphenyllaetic acid and 
p- hydroxyphenylpyruvic acid in the urine of premature infants fed on 
cows milk mixtures which were rich in protein but contained no 
vitamin C. The presence of abnormal amounts of p- hydroxyphenyl 
compounds has since been noted in the urine of adults with scurvy 
and also in the urine of patients suffering from pernicious anaemia, 
rheumatoid arthritis, and steatorrhoea (Rogers and Gardner, 1949; 
Swendseid, Burton and Bethel, 1943; Boscott and Cooke, 1954). 
Boscott and Cooke found that patients with steatorrhoea excreted 
large quantities of p- hydroxyphenylacetic acid in the urine and 
occasionally p- hydroxyphenyllaetic acid was also present. 
Administration of phenylalanine or tyrosine causes the excretion 
of increased amounts of these p- hydroxyphenyl compounds while 
administration of ascorbic acid brings about their disappearance 
from the urine. Administration of ascorbic acid has no effect on 
the excretion of homogentisic acid in congenital alcaptonuria. 
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One pathway of metabolism of phenylalanine and tyrosine which 
has been suggested is:- 
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acid acid 
and thence by opening of the benzine ring and oxidation to acetoacetic 
acid. Since in ascorbic acid deficiency p- hydroxyyphenylpyruvic acid 
and its derivatives p- hydroxyphenyllactic acid and p- hydroxyphenylacetic 
acid, are excreted in the urine it would appear probable that ascorbic 
acid is necessary for the hydroxylation of p- hydroxyphenylpyruvic 
acid to 2 :5 dihydroxyphenylpyruvic acid. There is experimental 
evidence in support of this view. 
Knox and Le-May Knox (1951), using enzyme systems prepared 
from rat liver have shown that tyrosine may be converted to 
acetoacetic acid in such systems. p- hydroxyphenylpyruvic acid, 
2 :5 dihydroxyphenylpyruvic acid and homogentisic acid are also 
converted to acetoacetic acid. v(- oxoglutarate and ascorbic 
acid are necessary to activate the enzyme system in the conversion 
of tyrosine to acetoacetic acid; o(- oxoglutarate is necessary for 
deamination of tyrosine and ascorbic acid catalyses the hydroxylation 
of p- hydroxyphenylpyruvic acid to 2 :5 dihydroxyphenylpyruvic acid. 
It is possible therefore that ascorbic acid may be necessary 
for the hydroxylation of proline to hydroxyproline. 
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These amino -acids represent approximately 30J of collagen 
and Stetten (1949) , found that labelled hydroxyproline when fed 
was not incorporated into collagen and concluded that the 
hydroxyproline of collagen is derived from proline. Gould and 
\ ;oessner (1957) found that in granulation tissue from regenerating 
skin in guinea -pigs there was considerable formation of hydroxy- 
proline. If, however, the animals were deprived of ascorbic 
acid for seven days there was almost complete cessation of 
hydroxyproline formation. Administration of ascorbic acid 
resulted in the formation of relatively large amounts of 
hydroxyproline within 21+ to 4.8 hours. 
Ascorbic acid metabolism in collagen diseases. 
The well -established fact of the failure of collagen formation 
in prolonged ascorbic acid deficiency naturally gives rise to 
speculation about a possible connection between ascorbic acid 
deficiency and the so- called "collagen diseases" in which group 
rheumatoid arthritis is included. From the observations of 
Crandon and Lund, however, it would appear that failure of 
collagen -formation as scurvy develops does not occur until even 
the leucocytes are depleted of ascorbic acid and there is no 
evidence of such a marked deficiency being a common feature in 
patients with rheumatoid arthritis. 
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In 1933 Rinehart and Mettier first suggested that a deficiency 
of ascorbic acid was a factor in the causation of rheumatic fever 
and in further papers over the next three years Rinehart and his 
associates developed this conception (Rinehart and Mettier, 1934; 
Rinehart, Connor and Mettier, 1934; Rinehart, 1935, 1936). 
Their conclusions were based on (1) the pathological changes found 
in guinea -pigs which had been inoculated with streptococcus after 
being maintained on a diet deficient in vitamin C, (2) a comparison 
of the joint changes in scurvy and rheumatic fever, and (3) 
considerations of the seasonal, geographical and social incidence 
of the disease. These workers suggested that a near -scurvy 
condition might also play a part in the aetiology of the more 
chronic condition of rheumatoid arthritis. 
These conclusions were not supported by any evidence based on 
biochemical investigation but in 1936 Rinehart, Greenberg and Baker 
reported the finding of low values of plasma ascorbic acid in 
patients suffering from rheumatoid arthritis. The plasma ascorbic 
acid rose to normal levels after treatment with large doses of 
ascorbic acid but it was noted that many cases were refractory to 
such treatment and that there appeared to be an increased requirement 
of ascorbic acid to maintain normal plasma levels. Similar findings 
in children with rheumatic fever were reported by Rinehart, 
Greenberg and Christie (1936). Low values for plasma ascorbic acid, 
as compared with levels in control groups, and delay in reaching 
normal levels on treatment with large doses of ascorbic acid were 
reported in rheumatic fever patients (Rinehart, Greenberg, Olney 
and Choy, 1938), in patients with rheumatoid arthritis (Rinehart, 
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et al, 1938) and in patients with rheumatoid spondylitis, 
(Rinehart, 1939). In a study of 55 patients with arthritis 
Rinehart and his co- workers observed that it was in arthritis 
of the rheumatoid type that plasma ascorbic acid levels were 
low (Rinehart, Greenberg, Baker, Mettier, Jruckman and Choy, 1938). 
Low levels of plasma ascorbic acid in rheumatoid arthritis have 
been reported also by Hall, Darling and Taylor (1939), Secher (1940), 
Jacques (1940), and Freyburg (1942). 
As early as 1936 Abassy, Gray Hill and Harris had noted a 
low urinary excretion of ascorbic acid, as compared with normal 
controls, in children with rheumatic fever, and similar findings 
were reported by Abassy and Harris (1937) and Hare and Williams 
(1938). Keith and Hickmans (1938), however, found that in 
children with rheumatic fever the 24 hour excretion of ascorbic 
acid was higher than in normal controls but, since salicylate 
therapy was not suspended, the higher ascorbic acid excretion 
was almost certainly due to the effect which this drug has on 
urinary excretion of ascorbic acid (Spitzer and Shapiro, 1948). 
Perry (1935), Schultz, Sendroy and Swift (1935) and Sendroy 
and Schultz (1936) measured the urinary excretion of ascorbic acid 
in patients with rheumatic fever before and airing a period on a 
fixed test dose of ascorbic acid and concluded that there was no 
evidence that a deficiency of vitamin C played any part in the 
aetiology of the disease, although the experimental results of 
both Perry and Sendroy and his co- workers indicated an increased 
requirement for the vitamin in rheumatic fever. Schultz (1936) 
repeated the experiments of Rinehart and his associates on guinea- 
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pigs rendered scorbutic and infected with streptococcus and 
expressed the opinion that the bone lesions produced only 
superficially resembled those found in rheumatic fever. 
Bayles, Richardson and Hall (1943) investigated the nutritional 
background of 31 patients with rheumatoid arthritis and could 
find no evidence that a previous dietary deficiency was 
responsible for the onset of the disease. 
Schroeder (1935), Harde, Rothstein and Ratish (1935), 
Bullowa, Rothstein, Ratish and Harde (1936) and other workers have 
shown that a deficiency state with regard to vitamin C exists in a 
variety of infectious conditions. Doubtless these reports, 
along with the lack of evidence of any amelioration produced by 
treatment with the vitamin in rheumatic conditions, was the chief 
reason for the investigation of the metabolism of ascorbic acid 
in rheumatoid arthritis not being pursued further. The view was 
fairly generally accepted that the low plasma levels and low urinary 
excretion of the vitamin in rheumatic fever was a phenomenon common 
to most infective conditions. However this may be true in the 
case of rheumatic fever there is no definite evidence that rheumatoid 
arthritis is due to an infection. 
Ascorbic acid and adreno- cortical function. 
Szent- Gyorgyi first showed in 1928 that there is a high 
concentration of ascorbic acid in the adrenal gland. _Previously, 
in 1926, Randoin and Michaux had reported that the cholesterol 
content of the gland was reduced in scurvy and Harris and Ray 
(1933) observed that the ascorbic acid content of the adrenal 
was reduced in scurvy. Giroud et al (1940) suggested that 
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ascorbic acid was necessary for the formation of adreno- cortical 
hormones from cholesterol. Long and his co- workers (Sayers, 
Sayers, Lewis and Long, 1944; Sayers, Sayers, Liang and Long, 
1945 and 1946) showed that ACTH depleted the adrenal cortex of 
rats of both ascorbic acid and cholesterol. Haemorrhage had the 
same effect but was without effect if the pituitory had previously 
been removed. These workers suggested that haemorrhage and other 
forms of stress stimulated the pituitary and that the consequent 
increased secretion of ACTH stimulated the adrenal cortex to 
produce cortico- steroids from cholesterol using ascorbic acid in 
the process. 
Some experimental evidence has been advanced in support of 
the theory that ascorbic acid is necessary for the production of 
the hormones of the adrenal cortex. Schaffenburg, Masson and 
Corcoran (1950) reported that cortisone inhibited many of the 
manifestations of scurvy in guinea -pigs maintained on a vitamin 
C -free diet and similar findings were reported by Herrick et al 
(1952) . Stefanñni and Rosenthal (1950) and Holley and McLester 
(1951) reported cases in which ACTH given to human patients over 
a long period had caused the development of symptoms similar to 
those of scurvy, although the evidence presented for the presence 
of scurvy was not very convincing. The inference would be that 
continued production of cortico- steroids under the stimulation of 
ACTH had exhausted the body reserves of ascorbic acid. The 
increased requirement for ascorbic acid observed in infectious 
conditions and following burns (Lund et al, 1947) might be taken 
as evidence in favour of such a theory. Itis known that 
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conditions of stress increase the production of adrenocorticotrophic 
hormone (ACTH) by the pituitary and hence the production of cortico- 
steroids. If ascorbic acid is necessary for the synthesis of 
these hormones this increased production of hormones would give 
rise to an increased requirement for ascorbic acid. Schmidt and 
Staudinger (1954) have reported that ascorbic acid, and also 
dehydroascorbic acid,activates the formation of corticosteroids 
in systems prepared from pigs adrenals. 
On the other hand Upton and Coon (1951) and Clayton and Prunty 
(1951) did not find that cortisone or ACTH had any effect on the 
course of experimental scurvy in guinea -pigs. In fact, Clayton 
and Erunty found an increased excretion of 17-ketosteroids in 
scorbutic guinea -pigs which would suggest an increased production 
of adreno- cortical steroids in spite of the ascorbic acid 
depletion. Hyman, Ragan and Turner (1950) reported that both 
cortisone and ACTH prolonged life and reduced the haemorrhagic 
manifestations of scurvy in guinea -pigs. There has been no 
reliable evidence that patients suffering from well- marked 
symptoms of scurvy show symptoms of adreno- cortical insufficiency 
such as are manifested in Addison's disease, and Treager et al 
(1950) reported that patients with marked clinical scurvy gave a 
normal response to the ACTH test (as evidenced by eosinophil count 
and serum electrolytes). Finally, there is the observation of 
Walbach and Maddock (1952) that cortisone has no effect on 
collagen- formation in scorbutic guinea -pigs. 
When beneficial results were obtained in rheumatoid arthritis 
by treatment with cortisone it was natural to infer a connection 
11. 
between rheumatoid arthritis and adreno- cortical activity and, if 
the production of the hormones of the adrenal cortex depended on 
a supply of ascorbic acid, this would imply a connection between 
ascorbic acid metabolism and rheumatoid arthritis. However, in 
the light of the conflicting evidence quoted a connection between 
ascorbic acid and adreno- cortical steroid production is far from 
being proved. Another possible connection between ascorbic acid 
and rheumatoid arthritis was introduced when Lewin and Wassen, in 
1949, claimed that simultaneous injections of ascorbic acid and 
deoxycorticosterone acetate (DOCA) produced clinical improvement 
in cases of rheumatoid arthritis. Similar reports of beneficial 
results from the simultaneous injections of ascorbic acid and 
DOCA were made by Le Vay and Loxton (1950) and Littman, Stockdale 
and Williamson (1951) and it was suggested that the effects of 
this combination were due to the conversion in the body of DOCA 
to an unspecified adreno- cortical hormone by ascorbic acid, 
(Hallberg, 1950). If such a conversion does occur it may be 
another instance of ascorbic acid being necessary for hydroxylation, 
in this case the introduction of a hydroxyl group at carbon atom 17. 
However, the investigations of Spies et al (194.9), Bywaters, Dixon 
and Wild (1950), Copeman et al (1950) and others failed to 
substantiate the therapeutic effect claimed for the combination 
of ascorbic acid and DOCA and it was found that it produced none 
of the biochemical effects of cortisone. 
There would appear therefore to be little evidence that a 
deficiency in respect to ascorbic acid is a causative factor in 
rheumatoid arthritis, that treatment with large doses of the vitamin 
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has any therapeutic effect in the condition - although Piassell et al 
(1950) claimed to have brought about clinical improvement by dosage 
of 4 g. ascorbic acid per day - or that the nutritional state with 
regard to the vitamin affects rheumatoid arthritis through 
production of adreno- cortical steroids. Nevertheless there were, 
between 1936 and 1942, repeated reports from various sources of 
low levels of plasma ascorbic acid, low urinary excretion and 
apparent increased requirement for the vitamin. A further 
investigation, using the newer techniques not available to the 
earlier workers, would appear to be warranted. Such an 
investigation should have as its objects firstly, to confirm or 
otherwise the findings of the earlier workers, and secondly, to 
bring to light any further differences that may exist between 
rheumatoid arthritis patients and non -rheumatoid subjects with 
respect to the metabolism of ascorbic acid. If such differences 
as are shown to exist point to an actual difference in the 
metabolic pathway of the vitamin in rheumatoid arthritis then an 
explanation of the nature of this difference in metabolism should 
be sought. 
Criteria of ascorbic acid deficiency. 
One method of assessing the state of nutrition with respect 
to ascorbic acid which has been extensively used is the ascorbic 
acid saturation test. A fixed dose of the vitamin, usually 
500 mg. or else 10 mg. per kilogram body weight, is given daily 
until "saturation ", as shown by the excretion in a 24 hour period 
of an arbitrarily chosen amount of ascorbic acid, is reached. 
The concept of "saturation" as applied to ascorbic acid has 
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been criticised (Bicknell and i'rescott, 1953) but, while it is true 
that a plasma ascorbic acid level such as it is necessary to attain 
before a sharp rise in urinary excretion occurs has never been shown 
to be physiologically necessary for the maintenance of health, yet 
the number of days required to reach such a level on a fixed daily 
dose of ascorbic acid does provide a rough indication of the state 
of nutrition of the subject with respect to the vitamin. The 
criticism has also been made that the conditions under which these 
tests are carried out vary so much that no conclusions can be taken 
from the data obtained but this objection is not valid if, in a 
single investigation, all the tests are carried out under the same 
conditions. A series of such tests on rheumatoid arthritis 
patients and non -rheumatoid controls might provide evidence as to 
whether there does indeed exist a deficiency of, or increased 
requirement for, ascorbic acid in rheumatoid arthritis. 
Many of the earlier workers cited a lower level of ascorbic 
acid in the plasma of rheumatoid arthritis patients as evidence of 
a deficiency of the vitamin. Confirmation of this must be sought 
but the methods used by these workers estimated ascorbic acid only, 
and, as has been shown by Stewart, Horn and Robson (1953), 
dehydroascorbic acid is also present normally in blood plasma and 
account must therefore be taken of the amount of both substances 
present in the plasma of rheumatoid arthritis patients and normal 
controls. The level in the blood plasma however, may not be the 
best index of the state of ascorbic acid nutrition or of body 
storage of the vitamin and some consideration must be given to 
this aspect of the problem. 
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Roe, Kueher and Zimler, in 1947, observed that the level of 
ascorbic acid in the plasma was lower than that of the erythrocytes 
when the level of ascorbic acid in both plasma and leucocytes was 
low but that these levels tended to reach equality as the ascorbic 
acid concentration in the blood increased, and Damron, Monier and 
Roe (1952) found that as the total ascorbic acid (i.e. ascorbic 
acid plus dehydroascorbic acid plus dioxogulonic acid) in all the 
tissues of guinea -pigs decreased in ascorbic acid deprivation it 
was in the amount present as ascorbic acid that the greatest 
decrease occurred. 
It has been shown (Lloyd, 1951; Golden and Sargent, 1952; 
Lloyd and Parry, 1954; Iggo, Thomson and Stewart, 1958) that 
the cell wall is readily pernable to dehydroascorbic acid but 
that ascorbic acid passes through the membrane only slowly. 
Stewart, Robson and Horn found (unpublished data) that dehydro- 
ascorbic acid was not formed in the plasma and it would appear from 
the experiments of Heinemann(1941) that the presence of leucocytes 
causes the conversion of ascorbic acid to dehydroascorbic acid 
which is then capable of passing into the erythrocytes where it is 
reduced again. It would appear therefore that the analysis of 
leucocytes or erythrocytes can provide no clear index of body store 
of the vitamin but since Crandon, Lund and Dill (1940) found that 
the appearance of scorbutic symptoms in prolonged ascorbic acid 
deprivation was preceded by the virtual disappearance of ascorbic 
acid from the leucocytes the level of ascorbic acid in the leucocytes 
has generally been taken as providing a rough indication of the body 
storage. 
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Iggo, Thomson and Stewart (1958) observed that the erythrocytes 
of rheumatoid arthritis patients reduced dehydroascorbic acid to 
ascorbic acid at a more rapid rate than did those of non -rheumatoid 
controls. Since dehydroascorbic acid can pass into the 
erythrocytes more easily than ascorbic acid can pass out of these 
cells it would be expected that this more rapid reduction of 
dehydroascorbic acid would lead to a depletion of the dehydro- 
ascorbic acid content of the plasma, other factors being equal. 
The investigation must include, therefore, the estimation of 
ascorbic acid and dehydroascorbic acid in plasma and erythrocytes, 
and of total ascorbic acid in leucocytes, of rheumatoid arthritis 
patients and normal controls. 
Some of the earlier workers found evidence of ascorbic acid 
deficiency in low urinary excretion but there was no uniformity in 
the intake of the vitamin during their experiments. A comparison 
of the excretion of ascorbic acid in the 24. hour period after a 
standard test dose of the vitamin in rheumatoid arthritis patients 
and controls would appear to be required and the carrying out of 
such tests on "unsaturated" subjects and on subjects who had 
already been brought to "saturation" level might yield useful 
information. 
Saturation tests should provide a rough measure of the tissue 
content, or body "reserve" of ascorbic acid, The plasma levels 
of ascorbic acid will reflect the recent intake of the vitamin in 
relation to body requirement while the plasma -erythrocyte ratio 
should give an indication as to the turnover. The amount of 
dehydroascorbic acid present, in relation to the "total" ascorbic 
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acid, in the plasma should indicate any difference in the rate of 
oxidation of the vitamin. If a difference in the metabolism of 
ascorbic acid does in fact exist in rheumatoid arthritis such a 
combination of tests should give some evidence of its existence 
and perhaps, of its nature. 
The metabolic pathway of ascorbic acid. 
In considering the question as to a possible difference in 
the metabolism of ascorbic acid between rheumatoid arthritis 
patients and the normal physiological condition it is necessary 
to review briefly what is at present known about the pathway of 
metabolism of ascorbic acid in the animal body. 
It has been known for some time that oxalic acid is one of 
the products of both the in vitro and in vivo oxidation of ascorbic 
acid (Herbert, Hirst, Percival, Reynolds and Smith, 1935; Jurist 
and Christiansen, 1939; Rosenfeld, 1943). In vitro ascorbic acid 
is reversibly oxidised to dehydroascorbic acid and thence, by rupture 
of the lactone ring, to dioxogulonic acid. Dioxogulonic acid may 
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In 1951 Burns, Burch and King using L- ascorbic -1 -C14 acid 
showed that in rats part of the oxalic acid excreted was derived 
from injected ascorbic acid and Hellman and Burns (1955) have 
demonstrated that in man also part of the excreted oxalic acid 
is derived from ascorbic acid. 
There is as yet no clear evidence that the pathway ascorbic 
acid - dehydroascorbic acid - dioxogulonic acid - oxalic acid is 
the main pathway in vivo. Damron, Monier and Roe (1952) as a 
result of their experiments on guinea -pigs gave as their opinion 
that the reaction ascorbic acid - dehydroascorbic acid - dioxo- 
gulonic acid was a "pathway of decomposition" rather than the 
normal metabolism in animal tissues. Curtin and King (1955) 
injected L- ascorbic -1 -C14 acid and similarly labelled dehydro- 
ascorbic acid and dioxogulonic acid into guinea -pigs and found 
the percentage conversion to respiratory C1402 in 22+ hours to 
be 19-, 29 and 1+7;% respectively. The corresponding conversion 
to urinary oxalate was 2L' with ascorbic acid, 9:] with dehydro- 
ascorbic acid and 1270 with dioxogulonic acid. When they 
injected oxalate containing C/4 only 0.1; appeared as respiratory 
CO2 /4 and they concluded that, in the rat, there was no evidence 
of conversion of oxalate to any other compound. 
Burns, Dayton and Schulenberg (1956) injected both carboxyl - 
and uniformly- labelled ascorbic acid into guinea -pigs and found 
that there was no significant difference in the proportion 
converted to C /402. They concluded that in the guinea -pig the 
main route of metabolism involves the oxidation of the entire 
carbon chain to carbon dioxide, smaller amounts being excreted 
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as ascorbic acid, dioxogulonic acid, and oxalic acid. It appears 
possible, therefore, that in the rat and the guinea -pi,7 the main 
pattern of metabolism is the oxidation of ascorbic acid via 
dehydroascorbic acid and dioxogulonic acid to carbon dioxide. 
Their experiments however provided no evidence as to whether 
oxalic acid was formed, with L- threonic acid, as intermediate 
products in the oxidation to carbon dioxide or whether it was 
the product of an alternative pathway of metabolism and was excreted 
unchanged. If ascorbic acid is converted to oxalic acid - via 
dehydroascorbic acid and dioxogulonic acid - and the oxalic acid 
is immediately oxidised further in some tissue enzyme system then 
the oxalic acid which reaches the plasma - and thence the excretory 
mechanism - may be an excess which escapes from the system. In 
this case any oxalic acid injected into the blood stream may easily 
be excreted unchanged and the fact that it is so excreted is no 
proof that oxalic acid formed in the tissues from ascorbic acid is 
excreted unchanged. 
Unfortunately there is less data available regarding the 
metabolic pathway in man. Hellman and Burns (1955) injected 
L- ascorbic -1 -C14 acid intravenously in two human subjects and 
found that no more than 10;0 appeared as respiratory CO 142 while 
approximately 70J was excreted in the urine - approximately 15:. 
of this was ascorbic acid, l5;; was dioxogulonic acid and 55, was 
oxalic acid. These results are surprising in view of the findings 
of Lambden and Chrystowski that the intake of ascorbic acid had 
to be raised to over 4 g. per day before any significant increase 
occurred in the urinary excretion of oxalate. There is no 
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evidence as yet as to whether oxalic acid is converted in the human 
body to any other substance or whether all the oxalic acid formed 
is excreted as such. Archer and his co- workers (1958) gave oxalic 
acid orally, as sodium oxalate, to two human subjects and calculated 
the increase in urinary oxalate to represent only 1.9' and 1.2 
respectively of the dose given. Since, however, they had no means 
of determining the levels of oxalate in the blood there is no 
evidence as to how much of the oxalate which was given was actually 
absorbed into the blood. It would be expected that most of such 
a dose, given orally, would form insoluble calcium and magnesium 
oxalates in the intestine and would therefore not be absorbed. 
It is known that eating rhubarb leaves or spinach, which contain 
appreciable amounts of soluble oxalate, tends to lower the body 
supply of calcium by binding the calcium in the diet as insoluble 
oxalate. 
Whatever the true facts are as to the metabolic pathway of 
ascorbic acid in man it would seem probable that if a difference 
in the metabolism of the vitamin does exist in rheumatoid arthritis 
such a difference may be reflected in some change in the rate of 
excretion of oxalic acid in the urine. Horn (1956) measured the 
urinary excretion of oxalate in rheumatoid arthritis patients and 
control subjects following very large oral doses of ascorbic acid 
and found that the excretion of oxalate was significantly lower in the 
rheumatoid than in the control group. Previous workers have 
reported lower urinary excretion of ascorbic acid in rheumatoid 
arthritis and the fact that excretion of oxalic acid is also 
lower in this condition is somewhat surprising, although it could 
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be explained by a failure in intestinal absorption of ascorbic 
acid in rheumatoid arthritis. To investigate this possibility 
and obtain further information about the excretion of oxalate in 
patients with rheumatoid arthritis it is required that Horn's 
experiments should be repeated but that the large doses of 
ascorbic acid should be given by the intravenous route. Another 
point requiring investigation is whether the state of nutrition of 
the rheumatoid arthritis patient with respect to ascorbic acid has 
any effect on the excretion of oxalic acid. In other words, if 
rheumatoid arthritis patients are brought to "saturation" level 
with large doses of ascorbic acid do they still excrete less 
oxalic acid than non -rheumatoid controls. 
MATRI.AL AND METHODS. 
21. 
Ì,41ATF2IAL AND AMHODS. 
(1) Subjects. 
All the rheumatoid arthritis patients who were subjects for 
the experiments were patients who were in bed in the Rheumatoid 
arthritis Unit wards in the Northern General Hospital. Most of 
the control subjects were patients in bed in the Neurological Unit 
at the same hospital who had been in hospital for several weeks and 
had received no vitamin supplement since admission. The 
exceptions were the control subjects in measurement of urinary 
excretion of ascorbic acid after 'saturation' with the vitamin 
and the control subjects in the experiments where cortisone and 
salicylate were given; members of the hospital staff were taken 
as controls for these experiments. 
(2) Ascorbic acid content of plasma. 
(a) "Total" ascorbic acid. 
The "total" ascorbic acid content of the plasma was estimated 
using the method of Roe and Kuether (191+3). In this method a 
trichloracetic acid extract of the plasma is shaken with an 
activated charcoal (Norit) to oxidise ascorbic acid to 
dehydroascorbic acid. The solution is then incubated with a 
sulphuric acid solution of 2 :1+ dinitrophenylhydrazine and the 
resulting coloured compound measured spectrophotometrically. It 
is probable that the 2:4 dinitrophenylhydrazine couples with 
dioxogulonic acid and under the experimental conditions there is 
rapid conversion of dehydroascorbic acid to dioxogulonic acid. 
The method therefore measures ascorbic acid plus dehydroascorbic 
acid plus dioxogulonic acid and it is the sum of these substances 
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that will be referred to as "total" ascorbic acid. 
Reagents. 1. 6 g. trichloracetic acid in 100 ml. water. 
2. Acid- washed Norit - 200 g. Norit were boiled 
with 1 litre 10;' hydrochloric acid and then filtered 
by suction. The Norit was transferred to a beaker, 
1 litre distilled water was added and after 
thorough stirring the mixture was filtered. 
The washing with water was repeated till the 
filtrate contained no ferric iron. The Norit was 
then dried at 110° to 120° C. 
3. 2:4 dinitropherylhydrazine solution - 2 g. 
dissolved in 100 ml. approximately 9 N sulphuric acid. 
4. 10 g. thiourea dissolved in 100 ml. ethanol - 
water (1 :1) 
5. 85; sulphuric acid - nine parts sulphuric acid 
added to one part water. 
Procedure. One part of plasma was added, slowly and with 
shaking, to three parts trichloracetic acid, mixed, and allowed to 
stand for 5 minutes. After centrifugation the supernatant fluid 
was pipetted off, shaken vigorously for 4. minutes with Norit 
(approximately 0.1 g. per ml.), and filtered. 
¿- ml. filtrate was placed in each of two test -tubes and one 
drop of thiourea solution was added to each tube. 1 ml. of 
dinitrophenylhydrazine reagent was added to one of the tubes which 
was then incubated at 37 00. for 3 hours. The second tube was kept 
as a blank and 1 ml. of the dinitrophenylhydrazine reagent was 
added to this tube at the end of the three hour period. Both 
Table A. 
Roe and Kuether method for "total" ascorbic acid. 
(1) Recovery of added ascorbic acid in plasma. 
Ascorbic acid added Ascorbic acid found 
mg. /100 ml. mg. /100 ml. 
Recovery 
.7 
1. Nil Nil 
2. Nil Nil 
3. Nil Nil 
4. 0.80 0.80 100.0 
5. 0.80 0.81 101.3 
6. 0.80 0.82 102.5 
7. 0.80 0.78 97.5 
8. 0.80 0.78 97.5 
9. 0.80 0.83 103.8 
Mean recovery 100.2; S.D. 0.02 mg. /100 ml. 
(2) Results of replicate determinations. 
Serum X 
Ascorbic acid 
mg. /100 ml. 
Serum Y 
Ascorbic acid 
mg. /100 ml. 
1. 2.29 1. 1.35 
2. 2.35 2. 1.39 
3. 2.45 3. 1.42 
4. 2.42 4. 1.37 
5. 2.36 5. 1.30 
6. 2.33 6. 1.38 
7. 2.36 7. 1.32 




S.D. 0.05 mg./loo ml. 
Mean 1.37 
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tubes were then immediately placed in an ice and water mixture 
and 5 ml. of 85 sulphuric acid were added, drop by drop, to the 
contents of each tube. The tubes were allowed to stand at room 
temperature for 30 minutes and then the optical density of the 
test solution was read on the Unicam Spectrophotometer S.P. 350 
at 505 114, the instrument being set to zero with the blank solution. 
With each batch of estimations a series of standard solutions 
containing 0.25, 0.50, 1.00, 1.50 and 2.00 mg. ascorbic acid per 
100 ml. were prepared. A one in four dilution of each standard 
solution with 6,C, trichloracetic acid was made and treated in the 
same way as the plasma filtrates. From the optical densities 
obtained from these standards a graph was made from which the 
concentration of "total" ascorbic acid in the plasma could be read. 
In a recovery experiment the equivalent of 0.8 mg. ascorbic 
acid per 100 ml. was added to a mixed specimen of old plasma which 
appeared to contain no ascorbic acid when tested by the Roe and 
Kuether procedure. Six determinations were made on the protein - 
free filtrate and the mean recovery was 100.) with a standard 
deviation of 0.02 mg. per 100 ml. Estimations of ascorbic acid 
were carried out on eight separate samples from one specimen of 
plasma and on ten separate samples from a second specimen of 
plasma and the standard deviation from the mean in these eighteen 
determinations was 0.05 mg. per 100 ml. The details of these 
experiments are set out in Table A. 
(b) Ascorbic acid content. 
The ascorbic acid content of plasma was determined by the 
Z+. 
method described by Stewart, Horn and ?obson (1953) using 2:6 
dichlorophenolindophenol. A measured amount of the dichloro- 
phenolindophenol solution is added to an aliquot of a 
metaphosphoric acid extract of the plasma and the optical density 
of the unreduced dye is measured in the photo -electric 
spectrophotometer. 
Reagents. 1. 2 :6 dichlorophenolindophenol solution - 
one tablet of B.D.H. dichlorophenolindophenol 
(stated to contain the equivalent of 1 mg. 
ascorbic acid) dissolved in 100 ml. water. 
2. 3 (w /v) metaphosphoric acid, freshly 
prepared each day. 
Procedure. Two volumes of plasma were added, slowly with 
shaking to three volumes of 3 metaphosphoric acid solution. 
lifter mixing and allowing to stand for a few minutes the mixture 
was centrifuged and the supernatant fluid filtered. 
Into a 10 m.m. cuvette was pipetted 2 ml. filtrate and 1 ml. 
dichlorophenolindophenol solution. After exactly 30 seconds the 
optical density was read on the Unicam Spectrophotometer S.P. 350 
at 520 r9.1., The instrument was set to zero with a blank prepared 
by adding 1 ml. of dye solution to 2 ml. of plasma filtrate and 
decolorizing with excess of solid ascorbic acid. A calibration 
curve was prepared for each batch of estimations from standard 
solutions of ascorbic acid in 1.8 (w /v) metaphosphoric acid. 
In a recovery experiment the equivalent of 0.80 mg. per 100 m1. 
ascorbic acid was added to old serum. The serum, before addition 
of ascorbic acid, was shown to contain no ascorbic acid by the 
Table B. 
Stewart, Horn and Robson method for ascorbic acid. 
Recovery of added ascorbic acid in plasma 
Ascorbic acid added 
mg/100 ml. 
Ascorbic acid Mima Recovery 
¡á mg. /100 ml. 
1 (a) Nil Nil 
(b) Nil Nil 
2 (a) Nil Nil 
(b) Nil Nil 
3 (a) 0.80 0.74 92.5 
(b) 0.76 95.2 
4 (a) 0.80 0.76 95.2 
(b) 0.75 93.8 
5 (a) 0.80 0.74 92.5 
(b) 0.75 93.8 
Mean recovery 93.8 7 S.D. 0.01 mg. /100 ml. 
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Stewart, Horn and Robson procedure. The mean recovery from 
duplicate determinations on each of the filtrates from three 
separate samples of serum was 93.E and the standard deviation 
from the mean was 0.01 mg. per 100 ml. The detailed results 
are given in Table B. 
Since this part of the work was completed a recent paper 
by Iggo, Owen and Stewart (1956) has shown that there is acid 
destruction of 2:6 dichlorophenolindophenol at the pH used in 
this method and, since the destruction does not appear to proceed 
at the same rate in the plasma filtrate as in the standard solution, 
they point out that this will lead to slightly low results for 
ascorbic acid. The error found in the recovery experiment is 
small and the results obtained varied from 0.04 to 0.06 mg. per 100 
ml. from the true value; since the results for both rhenmatoid 
arthritis patients and control subjects were obtained by the 
same method they are comparable. 
Owen and Iggo (1955) used p- chloromercuribenzoic acid to 
remove substances - chiefly thiols and thiosulphates - which 
interfere in the estimation of ascorbic acid when 2:6 
dichlorophenolindophenol is used. They found that when 
metaphosphoric extracts of human plasma were used the amount 
of interfering substance removed by p- chloromercuribenzoic acid 
was negligible and, therefore, it appears reasonable to assume 
that the substance estimated by this method is almost entirely 
ascorbic acid. 
(3) Ascorbic acid content of erythrocytes. 
The "total" ascorbic acid content of the erythrocytes was 
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obtained by the Poe and Kuether (1913) method. 
The ascorbic acid content was determined by reduction of 2:6 
dichlorophenolindophenol after saturation of the cells with carbon 
monoxide. Then blood erythrocytes are laked the release of 
haemoglobin into a medium containing copper ions results in the 
rapid and complete oxidation of all ascorbic acid present (Lemberg, 
Legge and Lockwood, 1939). Fujita, Ebihara and Numata (1939) 
suggested that blood should be saturated with carbon monoxide 
before estimation of ascorbic acid and a method using this 
technique was developed by Butler and Cushman (1940). Thomson 
(1955) adapted the method of Butler and Cushman for the estimation 
of ascorbic acid in erythrocytes and demonstrated that accurate 
estimation of ascorbic acid in erythrocytes could be obtained by 
this method. 
(4.) Ascorbic acid content of urine. 
'Total' ascorbic acid was estimated by the roe and Kuether 
method. For the estimation of ascorbic acid the method used was 
that described by Mapson (1953) as modified by Owen (Personal 
communication). The method is based on the fact that ascorbic 
acid condenses with formaldehyde to give a product which does not 
reduce 2 :6 dichlorophenolindophenol; the optimum pH for this 
condensation is 3.5 and the rate of condensation diminishes rapidly 
with decreasing pH till at pH 0.6 it is very slow. while interfering 
reducing substances - sulphydril derivatives, sulphides and 
thiosulphates - condense rapidly with formaldehyde at pH 0.6. 
The 2L hour urine was diluted to 2000 ml., if the volume was 
less than this, and an aliquot was adjusted to pH 0.6 with 503/ (vv) 
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sulphuric acid. To this was added 4 of its volume of 40; 
formaldehyde solution adjusted to pH 0.6 (sample A). Another 
aliquot of urine was adjusted to pH 3.5 with 3Dí; (w /v) sodium 
citrate solution and of its volume of 4O formaldehyde adjusted 
to pH 3.5 added (sample B). 
The reducing power of sample A was determined 15 minutes and 
again at 20 minutes after addition of formaldehyde by adding 2 ml. 
of sample to 5 ml. of phosphate- citrate buffer, pH 3.5, 1 ml. 30;-4 
sodium citrate and 2 ml. dichlorophenolindophenol solution and 
reading in the photo -electric colorimeter after 30 seconds. The 
reducing power of sample B was determined in the same way at 15 
minutes and 20 minutes after addition of formaldehyde, except that 
in this case 1 ml. water was substituted for 1 ml. 30 ¡'_ sodium 
citrate. The readings obtained were plotted on graph paper and 
by exterpolation the readings of A and B at zero time were obtained. 
From these readings, corrected for dilution, the reducing power of 
A and B in terms of ascorbic acid were obtained and the ascorbic 
acid concentration of the urine was given by A -B. A standard 
curve, obtained from freshly prepared solutions of ascorbic acid, 
was made with each batch of estimations. 
When a five -day old specimen of urine was examined by this 
procedure there was no difference in reducing power between the 
portion treated with formaldehyde at pH 0.6 and that treated at 
pH 3.5. The equivalent of 1.0 mg. ascorbic acid per 100 ml. was 
added to a portion of the urine and determinations on three separate 
samples gave results of 1.03, 0.95 and 0.94 mg. per 100 ml. However 
the method is time - consuming and, owing to the careful time -control 
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required, there were practical difficulties when a number of 
specimens had to be estimated at the same time. A further 
disadvantage was the fact that, when a number of estimations were 
being carried out simultaneously, there was a tendency for a white 
precipitate to form in the treated aliquots in spite of the volume 
of the 24-hour urine being diluted to 2000 ml. Accordingly in 
most of the experiments 'total' ascorbic only, by the Roe and 
Kuether procedure, was estimated. 
In the estimation of dehydroascorbic acid in urine the 
dehydroascorbic acid was reduced to ascorbic acid by passing H2S 
through the urine, which had previously been adjusted to pH 3.5 
with sodium citrate solution, for 30 minutes. The H2S was then 
removed from the urine by bubbling nitrogen through it for one 
hour. Ascorbic acid was then estimated by the modified Mapson 
procedure and the dehydroascorbic acid content obtained by 
difference. 
(5) Oxalate content of urine. 
In the estimation of urinary oxalate the method described by 
Powers and Levatin (1944) was used. These authors concluded that 
methods of estimating oxalate in urine by direct precipitation as 
calcium oxalate were unsatisfactory awing to interference by 
magnesium, sulphate and phosphate ions. In the method of Powers 
and Levatin the urine, after heating with hydrochloric acid to 
hydrolyse any oxaluric acid which may be present to oxalic acid, 
is extracted with ether in a continuous extraction apparatus. 
After removal of the ether the oxalic acid is precipitated as 





added and the excess permanganate is titrated iodometrically. 
Aparatu S. 
A diagram of the apparatus is shown in Fig. 1. The outer 
tube is 300 m.m. in length and 25 m.m. in diameter; the inner 
tube is 120 m.m. in length and 15 m.m. in diameter and is supported 
inside the outer tube by notches pushed into the glass 115 m.m. from 
the top of the tube. The funnel- shaped tube has an over -all length 
of 180 m.m. and the stem end is sealed and has four holes punched 
through the sealed end with a hot wire. When in position the extractor 
and the funnel- shaped tube are suspended from the top of the outer 
tube by lengths of cotton thread to assist in withdrawal at the end 
of the extraction period. A cold -finger condenser is placed in the 
top of the outer tube and the cotton thread serves to separate the 
condenser slightly from the rim of the tube, thus providing a vent. 
Reagents. 
(1) Concentrated hydrochloric acid. 
(2) Di -ethyl ether. 
(3) 25 (v /v) acetic acid in water. 
(4) Ethanol. 
(5) Acid -ethanol solution - 60 ml. ethanol, 
10 ml. 210 acetic acid and 20 ml. water. 
(6) 10 g. calcium chloride in 100 ml. water. 
(7) 2qß (v /v) sulphuric acid. 
(8) 1 g. manganese sulphate in 100 ml. water. 
(9) 10 g. potassium iodide in 100 ml. water. 
(10) 0.01 N potassium permanganate solution. 
(11) 0.01 N sodium thiosulphate solution. 
(12) 1% starch suspension. 
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.procedure. 
The 2A. hour urine specimen was thoroughly mixed and 25 ml. 
were pipetted into a boiling tube. 1 ml. concentrated hydrochloric 
acid was added, the contents mixed by gentle shaking, and the tube 
was heated in a boiling water -bath for 30 minutes in order to 
hydrolyse any oxaluric acid present to oxalic acid. The tube 
was then cooled and the urine filtered. 
In the outer tube of the extraction apparatus a small 
piece of capillary glass tubing was placed (to prevent "bumping ") 
and 2 ml. water and 25 ml. ether were added. 10 ml. of the 
filtered, hydrolysed urine were measured into the inner tube 
and extraction was carried out on an electric hot -plate for 
6 hours, the rate of heating being such that the ether dripped at 
the rate of at least 100 drops per minute. 
The apparatus was then disconnected and the inner tube 
removed after washing down with 2 ml. ethanol. 1 ml. of 2; 
acetic acid was added to the contents of the outer tube and the 
ether removed by immersion in a water -bath at 7000, with continuous 
shaking. The contents of the tube were then transferred by 
suction to a 15 ml. centrifuge tube. The walls of the outer 
tube were washed down twice with 2 ml. portions of ethanol and 
the rinsings transferred to the centrifuge tube. 
5 ml. of 10 calcium chloride solution were added to the 
contents of the centrifuge tube and mixed with gentle shaking. 
2 ml. of acid -ethanol solution were then layered on to the top 
of the liquid in the centrifuge tube to prevent any precipitate 
adhering to the surface of the liquid. After standing overnight 
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the tube was centrifuged at 2500 r.p.m. for 15 minutes, the liquid 
decanted from the precipitate and the tube inverted and drained on 
a filter -paper. 2 ml. acid -ethanol solution were added, the 
precipitle broken up with a glass rod, and the rod and sides of 
the tube washed down with 3 ml. acid -ethanol solution. The tube 
was centrifuged, decanted and drained as before and residual 
alcohol was removed by heating the tube in a boiling water -bath 
for a few minutes. 
1 ml. of 20; sulphuric acid was run into the tube and 0.5 ml. 
manganese sulphate solution. The precipitate was stirred up 
with a pointed glass rod which was rinsed with a few drops of 
water. 3 ml. 0.01 N potassium permanganate solution were added 
and the contents of the tube stirred, washing the rod as before. 
After 8 to 10 minutes, 0.5 ml. 10r potassium iodide solution was 
added and the liberated iodine was titrated with 0.01 N sodium 
thiosulphate solution, a few drops of starch suspension being 
added as the end -point was approached. A titration blank on the 
reagents was carried out using water instead of the oxalate 
solution. If t = the titration and b the blank titration, then 
oxalic acid content of 21+ hour urine is given by 
0.5 (3 - t - b) x 26 x volume 
of 24 hour urine 
25 25 
To test the reliability of the method a solution of 
potassium oxalate equivalent to 7.2 mg. oxalic acid per 100 ml. 
was prepared, the oxalate being dissolved in a solution containing 
magnesium, phosphate, sulphate and chloride in the average 
concentration present in urine, as suggested by Powers and Levatin. 
Determinations on six separate samples of this solution gave a 
Table C. 
Powers and Levatin method for urinary oxalate. 
Recovery of oxalate added to a solution containing 
magnesium, phosphate, chloride and sulphate. 
Oxalate added equivalent to 7.2 mg. oxalic acid per 100 ml. 
Oxalic acid found 
mg. /100 ml. 
Recovery 
1. 6.48 90.0 
2. 6.53 . 90.8 
3. 6.79 94.3 
4. 6.53 90.8 
5. 6.53 90.8 
6. 6.62 92.1 
recovery 91.4';(a S.D. 0.11 mg. /100 ml. 
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percentage recovery ranging from 90.0 to 94.3 and the standard 
deviation from the mean was 0.11 mg. per 100 ml. (Table C). 
(6) Ascorbic acid saturation tests. 
The subjects for these tests were receiving ordinary hospital 
diet, known to be low in ascorbic acid content, throughout the test 
period. For three days prior to the commencement of the test and 
during the test period any fruit or fruit drinks which might be 
brought to the patients were excluded from the diet. Drugs were 
withheld over the same period. 500 mg. ascorbic acid were given 
orally each day and a 2L. hour urine sample collected daily until 
'saturation' was reached. An excretion of 100 mg. or more ascorbic 
acid in one 24 hour period was taken as indicating saturation. Urine 
specimens were collected in a dark bottle which contained 40 g. 
crushed metaphosphoric acid and the bottles were stored in a cool, 
dark place till the collection was complete and analysis commenced. 
(7) Excretion of oxalate following intravenous ascorbic acid. 
The same dietary precautions were observed during these tests 
as in the ascorbic acid saturation tests and, in addition, any 
article of food known to contain an appreciable amount of oxalate 
was excluded from the diet. Drugs were withheld for three days 
prior to, and during, the test period. 24 hour urine specimens 
were collected for two days and on the morning of the third day 
5 g. ascorbic acid (Roche ascorbic acid for intravenous injection) 
was injected intravenously in a 10% solution. 24 hour urine 
specimens were collected on the third and fourth days and 
estimation of ascorbic acid and oxalic acid were carried out on 
each 24 hour specimen. Urine was collected in a dark bottle 
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containing 40 g. crushed metaphosphoric acid and 4 g. thiourea, 
and the bottle was stored in a dark, cool place till collection 
was complete. The estimation of ascorbic acid and oxalic acid 




Time required to reach "saturation" on 500 mg. ascorbic 
acid per day. 
Ranc-e 
i.on-rheumatoid subjects (16) 2 to 7 days 
Rheumatoid patients (21) 3 to 8 days 
11t11 = 2.72 p 
ï:ean .D. 
1+.3 days 1.3 
5.5 days 1.4 
= less than 0.05. 
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EXEERIMEETAL RESULTS. 
(1) Ascorbic acid saturation tests. 
Ascorbic acid saturation tests were carried out on a group 
of 21 patients with rheumatoid arthritis and on 16 control subjects. 
The results of the tests are given in Table 8 in the Appendix and 
are summarised in Table 1. There was considerable variation within 
each group in the number of days required to reach saturation although 
all the subjects were receiving the same dietary intake of ascorbic 
acid; in the rheumatoid arthritis group a period of from 3 to 8 
days was required to reach saturation level while in the control 
group the time required ranged from 2 to 7 days. Although the 
difference between the two groups does not appear to be a large 
one a statistical analysis shows that it is, in fact, significant. 
The mean tine required for saturation in the rheumatoid arthritis 
group was 5.5 ± 1:3 days and in the control group 4.3 ± 1.4 days. 
"Students" "t" test shows the difference to be significant, 
"t"= 2.72 and "p" less than 0.05. 
To determine if changing the arbitrarily- chosen level of 
urinary excretion of ascorbic acid taken as indicating "saturation" 
made any difference to the comparison of the groups the statistical 
analysis was repeated taking, this time, an excretion of 50 mg. 
ascorbic acid in a 24 hour period as representing "saturation ". 
In this case the difference between the two groups was still 
significant, "t" = 2.36 and "p" less than 0.05. 
The results of the saturation tests, therefore, show that 
the rheumatoid arthritis patients tend to require a longer period, 
on the same daily oral dose of ascorbic acid, to reach saturation 
TL; 2. 
Excretion of ascorbic acid after test dose of 500 m:1. 
r. Unsaturated subjects 
Non- rheumatoid (17) 
Range 
3 to 64 mg/24 hrs. 15.8 mg. 
Rheumatoid arthritis (16) 2 to 14 mg/24 hrs. 
2.2L- 
B. "Saturated" subjects 
Non- rheumatoid 
(11 estimations on 
Rheumatoid arthritis 






= less than J.05 
Range 
264 to 382 
mg/ 24 hrs. 








327 mg. 45.2 
302 mg. 59.5 
= greater than 0.05. 
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than do normal controls. 
(2) Excretion of ascorbic acid after a test dose. 
In Table 2 is given a summary of the results obtained for the 
excretion of ascorbic acid in the 24 hour period following a single 
test dose of 500 mg. ascorbic acid, given orally, in a number of 
rheumatoid arthritis patients and non -rheumatoid controls and the 
full results are given in the Appendix, Table 9. The subjects 
included in the "unsaturated" groups had been receiving the ordinary 
hospital diet without vitamin supplementation for two or three weeks 
before the tests were made. The subjects in the "saturated" 
groups had received a supplement of 500 mg. ascorbic acid daily 
for at least eight days (the longest period which had been found 
necessary to reach saturation in the saturation tests) immediately 
prior to the test period. 
When the subjects were "unsaturated" there was a significant 
difference between the response to the test of the two groups. 
The range of the excretion of ascorbic acid in the 24 hour period 
was 2 to 14 mg. (mean 7.7 
t 
4.4 mg.) in the rheumatoid arthritis 
group. In the control group there was a much wider range in the 
results which varied from 3 to 64 mg. in the 24 hour period (mean 
15.8 ± 4.4 mg.) . When the subjects were saturated there was a 
wide variation in the results obtained in both groups, the range 
being 213 to 14) mg. per 24 hours (mean 302 59.5 mg.) for the 
rheumatoid arthritis patients and 264 to 382 mg. per 21. hours 
(mean 327 
± 
45.2 mg.) for the control subjects, and there was no 
statistically significant difference between the groups. 
The results confirm the findings of earlier workers that 
TjBT,1 3. 
"Total" ascorbic acid content of plasma and erythrocytes. 
:Plasma ascorbic acid. 
Range 
Eon-rheumatoid (12 subjects) 0.06 to 0.58 mg. 
/100 ml. 
Rheumatoid (23 subjects) 
rtttt = 0.50 





erythrocyte ascorbic acid 
minus plasma ascorbic acid. 
Eon- rheumatoid 
Rheumatoid arthritis 
"t" = 4.37 







greater than 0.1 
0.15 to 0.30 mg. 
/100 ml. 







= less than 0.05 
0.05 to 0.22 mg. 
/100 ml. 














rheumatoid arthritis patients tend to excrete less ascorbic acid 
than normal controls receiving the same intake but it appears that 
once the tissues are saturated with ascorbic acid the rheumatoid 
patients excrete approximately the same proportion of a test dose 
as do non -rheumatoid controls. 
(3) Plasma ascorbic acid. 
A study was made of the level of "total" ascorbic acid in a 
number of rheumatoid arthritis patients and non -rheumatoid controls; 
a summary of the results is given in Table 3, and the results are 
given in full in Tables 10 and 11 in the Appendix. In both groups 
there was considerable variation in the level of the plasma "total" 
ascorbic acid, the range in the rheumatoid arthritis group being 
0.03 to 0.58 mg. per 100 ml. (mean 0.22 
± 
0.17 mg.) and in the 
control group 0.06 to 0.58 mg. per 100 ml. (mean 0.25 ± 0.17 mg.). 
The results in the two groups do not differ significantly and the 
findings would appear to be at variance with those of the earlier 
workers. However the concentration of ascorbic acid itself was 
estimated in the plasma in a number of subjects in both groups 
(Table 12, Appendix, summarised in Table 4) and if these are 
compared it is seen that there is a lower concentration of 
ascorbic acid (and hence, presumably a higher concentration of 
dehydroascorbic acid + dioxogulonic acid) generally in the plasma 
of the rheumatoid arthritis patients than in the plasma of the 
control group. The ratio 
ascorbic acid 
was 0.36 to 0.85 
total ascorbic acid 
(mean 0.63 It 1.7) in the rheumatoid arthritis group and 0.61 to 
0.96 (mean 0.81 ± 0.12) in the control group. Even when the 
intake of ascorbic acid was 500 mg. per day there was still a 
TABLE 1+. 
Ascorbic acid and "total" ascorbic acid content of plasma. 
A. Low ascorbic acid intake 
plasma ascorbic acid 
(50 mg. per day) . Ratio plasma "total" ascorbic acid 
Range :Jean S.E. 
Non-rheumatoid 0.61 to 0.93 0.81 0.12 
(8 determinations on 1+ subjects) 
Rheumatoid arthritis 0.38 to 0.85 0.63 0.17 
(11 determinations on 5 subjects) 
t = 2.56 "p" = less than 0.05. 
B. High ascorbic acid intake 
(500 mg. per day). 
Non- rheumatoid 0.86 to 0.99 0.95 0.06 
(L determinations on 2 subjects) 
Rheumatoid arthritis 0.L7 to 0.87 0.73 0.15 
(8 determinations on 3 subjects) 
"t" = 2.70 = less than 0.05. 
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significant difference between the two groups the ratio 
ascorbic acid 
being 0.47 to 0.87 (mean 0.73 ± 0.15) for the total ascorbic acid 
rheumatoid group and 0.86 to 0.99 (mean 0.95 
t 
0.06) for the control 
group. Therefore, irrespective of the amount of dietary intake of 
ascorbic acid there is a tendency for rheumatoid arthritis patients 
to have a higher plasma content of dehydroascorbic acid than control 
subjects receiving the same intake. 
(L1) Ascorbic acid content of erythrocytes. 
The "total" ascorbic acid was estimated in the red blood cells 
of the subjects in both groups at the same time that the plasma 
ascorbic acid estimations were made. An estimation of the ascorbic 
acid content of the erythrocytes was obtained in a number of these 
cases in both the rheumatoid arthritis and control groups. In all 
these subjects, in both groups, the dehydroascorbic acid content of 
the erythrocytes as measured by the difference between the ascorbic 
acid content and "total" ascorbic acid content was negligibly small. 
The results are given in the Appendix, Tables 10, 11 and 13. 
The estimation of "total" ascorbic acid in the erythrocytes 
disclosed a difference between the two groups of subjects; in the 
rheumatoid group the "total" ascorbic acid content of the erythrocytes 
was usually higher than the concentration in the plasma while in the 
control group this was not so. Correspondingly while there was no 
significant difference between the plasma "total" ascorbic acid 
levels in the two groups the concentration of "total" ascorbic acid 
in the erythrocytes was higher in the rheumatoid arthritis patients. 
The range was 0.22 to 1.4.2 mg. per 100 ml. (mean 0.54.t 0.29 mg. per 
100 ml.) in the rheumatoid group and 0.15 to 0.80 mg. per 100 ml. 
TABLE 5. 
Ascorbic acid content of leucocytes. 
3ange ì:_ean 
Iron- rheumatoid 5.0 to 20.5 12.5mg/100 inl. 6.3 
(8 determinations on 6 subjects) mg/100 ml. 
- 'rheumatoid arthritis 2.1 to 10.0 5.9mg/100 ml. 2.7 
(11 determinations on 10 subjects) mg/100 ml. 




0.18 mg. per 100 ml.) in the control group, a 
significant difference. If the erythrocyte - plasma difference 
is compared it will be seen that there is a highly significant 
difference between the two groups, the range of this difference 
(erythrocyte "total" ascorbic acid minus plasma "total" ascorbic 
acid) being 0.10 to 0.84 mg. per 100 ml. (mean 0.33 ± 0.17 mg. 
per 100 ml.) in the rheumatoid arthritis group and - 0.05 to 0.22 
mg. per 1u0 ml. (mean 0.10 
± 
0.08 mg. per 100 ml.) in the control 
subjects. (Table 3). 
(5) "Total" ascorbic acid content of leucocytes. 
In Table 5 a summary of the results obtained for the "total" 
ascorbic acid content of the leucocytes in ten rheumatoid arthritis 
patients and six control subjects is given. In the rheumatoid 
arthritis group the range was 2.1 to 10.0 mg. per 100 g. (mean 
5.9 - 2.7 mg. per 100 g.) and in the control group 5.0 to 20.5 
mg. per 100 g. (mean 12.5 
± 
6.3 mg. per 100 g.). The ascorbic 
acid content of the leucocytes is significantly lower in the 
rheumatoid group than in the control group. The full results 
are shown in Table 11+ in the Appendix. 
(6) Urinary excretion of oxalic acid. 
In the period before the injection of ascorbic acid the 
excretion of oxalic acid was significantly lower in the rheumatoid 
arthritis group, a finding that is in conformity with the results 
obtained by Horn (1956). In eleven rheumatoid arthritis patients 
the excretion of oxalic acid in this period was 28.4 to 68.0 mg. 
per 48 hours (mean 48.4 ± 13.6 mg) and in ten experiments on nine 
non -rheumatoid controls it was 1+8.1 to 91.1 mg. per 48 hours 
TABLE 6. 
I. excretion of oxalic acid. 
A. Non- rheumatoid aubjects, "unsaturated" before injection of 
ascorbic acid (10 subjects) 
Range 48.1 to 91.1 mg/48 hours. Lean 69.4 mg. S.D. 16.6 
B. Rheumatoid arthritis patients, 
of ascorbic acid (11 subjec 
Range 23.4 to 68.0 mg/48 hours. 
C. Rheumatoid arthritis patients, 
of ascorbic acid (8 subject 
Range 26.6 to 74.3 mg/48 hours. 
"unsaturated ", before injection 
ts`' 
Mean 48.4 mg. S.D. 13.6 
"saturated ", before injection 
s) . 
Comparison of n with 3, "t" = 3.10, 
Comparison of A with C, "t" = 2.59, 
'jean 48.0 mg. S. D. 16.2 
"p" 
less than 0.01 
= less than 0.05. 
II. Increase in excretion of oxalic acid in 48 hours after 
injection of 5 g. ascorbic acid. 
A. Non-rheumatoid subjects, "unsaturated ". 
Range 6.1 to 95.6 mg. Mean 35.6 mg. 
B. Rheumatoid arthritis patients, "unsaturated ". 
Range: decrease of 14.3 mg. to increase of 51.2 mg. 
Mean increase 10.8 mg. 
C. Rheumatoid arthritis patients, "saturated ". 
Range: decrease of 14.4 mg. to increase of 47.8 mg. 
Mean increase 10.8 mg. 
Comparison of A with 3, 
Comparison of A with C, 
,,.t" 
"t,r 
= 2.29, "p" = less than 0.05 
2.14, "p" = less than 0.05. 
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(mean 69.1 ± 16.6 mg.). The increase in oxalic acid excretion 
in the 148 hours immediately following the intravenous injection 
of 5 g. ascorbic acid was also significantly lower in the rheumatoid 
arthritis group. In this group the results varied from a decrease 
of 114.3 mg. to an increase of 51.2 mg. (mean increase 10.8 mg.) , 
the corresponding results for the control group being an increase 
ranging from 6.1 mg. to 95.6 mg. in 48 hours (mean increase 35.5 mg.) . 
When the increase in the excretion of ascorbic acid in the 48 hours 
following the injection, compared with the ¿8 hours before injection, 
was subtracted from the dose injected and the increase in excretion 
of oxalic acid was calculated as a percentage of this "unaccounted 
for" ascorbic acid the mean percentage was 1.26 ± 2.71 for the 
rheumatoid group and 6.56 ± 7.03 for the control subjects. That 
is, of that portion of the injected ascorbic acid which is not 
excreted as such, or as dehydroascorbic acid or dioxogulonic acid, 
a smaller proportion is excreted as oxalate by rheumatoid arthritis 
patients (Table 6) . 
I am indebted to Dr. D. B. Horn for permission to include the 
results of one test on a rheumatoid arthritis patiant and five tests 
on control subjects, carried out by him, in this series. 
The tests were repeated on a number of rheumatoid arthritis 
patients who had received 500 mg. ascorbic acid per day, orally, 
for nine days prior to the commencement of the test. Although 
these "saturated" subjects were still receiving the supplement of 
500 mg. ascorbic acid daily, the range of the excretion of oxalic 
acid in the 48 hours before the intravenous injection of ascorbic 
acid was almost identical with that obtained for "unsaturated" 
TA.13LE, 7. 
Excretion of ascorbic acid in 48 hours after injection of 
5 g. ascorbic acid. 
Range Mean S.D. 
_:on- rheumatoid (10 subjects) 2021 to /i)178 mg. 3351 mg. 760 




= greater than 0.1 
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rheumatoid arthritis patients and again significantly lower than 
that obtained with "unsaturated" control subjects. The range 
was 26.6 to 71+.3 mg. oxalic acid per 1+8 hours (mean 1+8.0 ± 16.2 mg.) . 
The difference in excretion of oxalic acid in the 48 hours 
immediately following the intravenous injection of 5 g. ascorbic 
acid varied from a decrease of 14.4 mg. to an increase of 1+7.8 mg. 
(mean increase 10.8 mg.) per 48 hours. Again the results are very 
similar to those obtained in "unsaturated" rheumatoid arthritis 
patients and the increase in excretion of oxalate is significantly 
less than that obtained in "unsaturated" control subjects. The 
full results for the excretion of oxalic acid are given in the 
Appendix, Tables 15 to 17. 
(7) Effect of cortisone and salicylate on blood levels, and 
urinary excretion, of ascorbic acid. 
Since cortisone and salicylate are drugs of proved therapeutic 
value in the treatment of patients suffering from rheumatoid 
arthritis experiments were carried out to test the effect of 
these drugs on the levels of ascorbic acid in the plasma and 
erythrocytes and on the urinary excretion of ascorbic acid in 
rheumatoid arthritis patients and non -rheumatoid control subjects. 
Two rheumatoid patients and two control subjects received 50 mg. 
ascorbic acid daily throughout the test period while two control 
subjects and three rheumatoid subjects, after a preliminary 
period on 50 mg. per day, received 500 mg. ascorbic acid daily 
for the remainder of the test period. One of the rheumatoid 
patients on the low ascorbic acid intake and one on the high 
intake was given cortisone while the other rheumatoid arthritis 
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subjects were given salicylate, both drugs being given in ordinary 
therapeutic doses. In each pair of control subjects receiving the 
same supplement of ascorbic acid one subject was given cortisone 
and one salicylate. Daily 24 hour collections of urine were 
obtained throughout the test period for the estimation of 
ascorbic acid and dehydroascorbic acid. Blood was withdrawn 
twice during each sub -section of the test period, usually of five 
days duration, for the estimation of ascorbic acid and "total" 
ascorbic acid in the plasma and erythrocytes. 
The results are shown in Tables 18 to 26 in the Appendix. 
In the subjects who received a low ascorbic acid intake neither 
cortisone nor salicylate appeared to have any clearly- defined 
effect on the concentration of ascorbic acid and dehydroascorbic acid 
present in the plasma or erythrocytes, or on the urinary excretion. 
The rheumatoid arthritis patients who received the high ascorbic 
acid intake showed a marked rise in both the plasma and erythrocyte 
levels of ascorbic acid and in the amount excreted in the urine 
immediately following the start of the cortisone or salicylate 
therapy. The two control subjects who received a high intake 
of ascorbic acid had reached "saturation" level before the 
cortisone or salicylate dosage was commenced and the drugs 
appeared to produce no appreciable change in the concentration 
of ascorbic acid in plasma or erythrocytes. 
In both these subjects the excretion of ascorbic acid in 
the 24 hour urine increased to over 500 mg. in the first period 
after commencement of dosage with the drug but this effect was 
not maintained. In the rheumatoid arthritis patients the 
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concentration of plasma dehydroascorbic acid, which was generally 
higher than in the non -rheumatoid subjects, appeared to be reduced 
as a result of the cortisone or salicylate therapy. 
In order to investigate further the effects of cortisone and 
salicylate on blood levels and urinary excretion of ascorbic acid 
in rheumatoid arthritis patients experiments were carried out over 
a much longer period on a few subjects. These patients received 
ordinary hospital diet without vitamin supplement or drugs for 
two weeks; during the following two weeks 500 mg. ascorbic acid 
was given orally every day and during a third period of two 
weeks cortisone or salicylate (in normal therapeutic doses; was 
given in addition to 500 mg. ascorbic acid per day. This 
period on one or other of the drugs was followed by two weeks on 
500 mg. ascorbic acid daily but with no drugs and, finally, by 
a two week period on hospital diet without ascorbic acid supplement 
or drugs. 24. hour urine specimens were collected every second day 
throughout the test period of ten weeks and blood samples were 
withdrawn at seven day intervals for estimation of "total" 
ascorbic acid in plasma and erythrocytes. 
The results obtained from these experiments are shown in 
the Appendix, Tables 27 to 32 and suggest that in rheumatoid 
arthritis patients, once "saturation" level has been obtained, 
cortisone and salicylate cause no change in the plasma or 
erythrocyte level of ascorbic acid. In some of the subjects 
there was evidence of an increased urinary output of ascorbic 
acid immediately following commencement of dosage with cortisone 




The experimental results confirm the findings of Rinehart and 
his associates and the other earlier workers that in general there 
is a lower concentration of ascorbic acid in the plasma of 
rheumatoid arthritis patients, and a lower excretion of the 
vitamin in the urine, than in non -rheumatoid subjects, receiving 
the same amount of dietary ascorbic acid. The results obtained 
in the ascorbic acid saturation tests support the view that there 
exists a deficiency of ascorbic acid, or an increased requirement 
for the vitamin, in the rheumatoid condition. Further differences 
between rheumatoid arthritis patients and normal controls have 
been demonstrated in the course of the investigation; it has 
been shown that rheumatoid arthritis patients have a higher 
concentration of dehydroascorbic acid in the plasma and a higher 
concentration of ascorbic acid in the erythrocytes than normal 
controls; that they have a lower concentration of "total" ascorbic 
acid in the leucocytes, and that they excrete less oxalate in the 
urine than normal subjects when the intake of ascorbic acid is 
the same. The question arises therefore as to how far this new 
data contributes to providing an explanation of the apparent 
deficiency of ascorbic acid in the rheumatoid condition. 
Of the possible explanations which might be advanced for this 
apparent deficiency those most worth consideration would appear to 
be (a) a poor dietary intake, (b) a defect in intestinal absorption 
in rheumatoid arthritis patients, (c) an alteration in the rate of 
urinary excretion of ascorbic acid, (d) some alteration in the 
144. 
body storage and (e) an alteration in the metabolism of the vitamin 
which might involve either increased destruction, whether useful 
or wasteful, or an altered pathway of metabolism. 
A point that has been advanced in favour of the view that 
the deficiency is due to a poor dietary intake is that there is an 
almost complete absence of rheumatoid arthritis in the Tropics 
where true clinical scurvy is practically unknown. However there 
appears to be some doubt as to the truth of the claim concerning 
the absence of rheumatoid arthritis in the Tropics and, in any 
case, in view of the different climatic conditions any difference 
in the incidence of the disease between the Tropics and other 
zones can not be attributed solely to dietary factors. Under 
present conditions true clinical scurvy is a very rare condition 
in this country and there is no evidence that the incidence of 
rheumatoid arthritis is confined to those social classes in which 
scurvy does occasionally occur. On the contrary scientifically 
conducted surveys in both Europe and America have shown that the 
disease occurs in all social groups and in widely differing 
climatic conditions. It seems unlikely therefore that dietary 
intake can play any important part in the causation of the disease 
or of the deficiency in ascorbic acid which appears to accompany it. 
This view is supported by the work of Bayles, Richardson and Hall 
(191+3) who examined the nutritional background of thirty -one 
patients with rheumatoid arthritis; they found that only eight 
had an intake of below 25 mg. per day and sixteen had an intake 
of over 50 mg. per day - up to as high as 160 mg. per day - and 
they concluded that there was no evidence that a previous dietary 
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deficiency played any part in the aetiology of rheumatoid arthritis. 
The lower plasma levels and decreased urinary excretion of 
ascorbic acid in rheumn toid arthritis patients and the longer time 
required to reach saturation on a standard daily dose of the vitamin 
could be explained, given similar intakes, by a diminished rate of 
intestinal absorption. Such a defect in absorption might have 
explained the lower excretion of oxalic acid in rheumatoid 
arthritis reported by Horn (1956) and confirmed in the present 
investigation, but rheumatoid arthritis patients showed a smaller 
increase in oxalate excretion after intravenous doses of ascorbic 
acid (Table 6) and in this case intestinal absorption was not 
involved. When the "total" plasma ascorbic acid was measured 
(Table 3) there was no difference between the rheumatoid and 
control groups while in the erythrocytes the level of ascorbic 
acid was actually higher in the rheumatoid arthritis patients than 
in the controls when both groups received the same intake of 
ascorbic acid. (Table 3). It is difficult to reconcile these 
findings with a diminished rate of intestinal absorption of 
ascorbic acid. 
rx diminished rate of renal excretion of ascorbic acid could 
be the explanation of the lower excretion of ascorbic acid 
observed in rheumatoid arthritis patients and for the longer time 
required to reach an arbitrarily chosen level of excretion in the 
ascorbic acid saturation tests. Ralli, Friedman and Rubin (1938) 
found that the excretion of ascorbic acid was governed by (1) the 
plasma level, (2) the rate of glomerular filtration and (3) the 
maximal rate of tubular re- absorption, so that a diminished 
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excretion might arise because of a defect in glomerular filtration 
or an abnormally high rate of tubular re- absorption. It would 
be possible to obtain figures ostensibly representing the rate of 
glomerular filtration and the rate of tubular re- absorption in 
rheumatoid arthritis patients and control subjects but, owing to 
the labile nature of ascorbic acid and dehydroascorbic acid. such 
measurements woul.d be of little value. There could be no means 
of taking into account any interconversion of ascorbic acid and 
dehydroascorbic acid, or of any destruction of ascorbic acid 
via dioxogulonic acid, in the tubules or in the cells of the 
tubules. However, it is worthy of note that when rheumatoid 
and control subjects had been brought to a state of "saturation" 
with large doses of ascorbic acid there was no significant difference 
in the 24 hour excretion after a test dose between the two groups 
(Table 2). Similarly, there was no significant difference between 
rheumatoid arthritis and control subjects in the amount of ascorbic 
acid excreted in the 48 hours after the intravenous injection of 
5 g. ascorbic acid (Table 7), when very large amounts - up to 
4 g. in 24 hours - were excreted. It does not appear therefore 
that there is any inability to excrete ascorbic acid on the part 
of the rheumatoid arthritis patient. 
An attempt to explain the apparent deficiency of ascorbic 
acid observed in rheumatoid arthritis on the basis of dietary 
intake, diminished intestinal absorption or a decreased rate of 
urinary excretion would still leave the new facts brought to light 
in the present investigation. None of these theories would 
explain the higher concentration of dehydroascorbic acid found 
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in the plasma or the higher concentration of ascorbic acid in the 
erythrocytes of rheumatoid arthritis patients and it appears 
unlikely that these differences between rheumatoid arthritis and 
normal subjects should be unrelated to the difference in plasma 
ascorbic acid level and urinary excretion between the groups. 
Booker et al (1951) found evidence of a barrier between 
plasma and cells towards ascorbic acid, but their methods estimated 
ascorbic acid only and did not take account of dehydroascorbic acid. 
From the work of Lloyd (1951), Golden and Sargent (1952) and Lloyd 
and marry (1954), and confirmed by Iggo, Stewart and Thomson (1958), 
it is now known that the cell wall is readily permeable to 
dehydroascorbic acid but that ascorbic acid passes through it only 
slowly. It has been found (Stewart, Horn and Robson, personal 
communication), that dehydroascorbic acid is not produced, to any 
appreciable extent, in the plasma and hence the higher concentration 
of dehydroascorbic acid in the plasma must be due to a tissue 
process. Iggo, Thomson and Stewart (1958) have shown that the 
erythrocytes of rheumatoid arthritis patients reduce dehydroascorbic 
acid more readily than do those of non -rheumatoid controls. Thus, 
as a consequence of increased oxidation of ascorbic acid to 
dehydroascorbic acid in the rheumatoid patient, dehydroascorbic 
acid would be expected to pass into the erythrocytes at a greater 
rate and there to be reduced to ascorbic acid which will be retained 
within the cell membrane; this is the picture actually found. 
An increased intake of dehydroascorbic acid into the cells 
and its conversion there to ascorbic acid leading to an increased 
concentration of ascorbic acid in the cell suggests the possibility 
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that the lowered plasma levels and decreased urinary excretion of 
the vitamin in rheumatoid arthritis may be due to an increased 
tissue storage. It is not known however if this phenomena of 
reduction of dehydroascorbic acid takes place in cells other than 
the erythrocytes. Since it has been demonstrated by Crandon and 
his co- workers and others that the appearance of symptoms of scurvy 
in prolonged ascorbic acid deprivation is heralded by the virtual 
disappearance of ascorbic acid from the leucocytes the concentration 
in the leucocytes has generally been taken as providing the best 
indication - short of the analysis of biopsy material from various 
organs - of the state of body storage. The ascorbic acid content 
of the leucocytes was lower in the rheumatoid arthritis group than 
in the control subjects which would suggest a lower than normal 
body store. 
If, however, there is no difference in intake, absorption or 
excretion of ascorbic acid the explanation of a lower body store 
remains to be found and the answer must surely lie in an alteration 
of metabolism. The higher concentration of ascorbic acid in the 
erythrocytes can be understood as a consequence of the higher 
plasma concentration of dehydroascorbic acid since not only must 
there be an unusually rapid passage of dehydroascorbic acid into 
the erythrocytes, but there is unusually rapid regeneration of it 
into ascorbic acid within the erythrocytes. This, in turn, argues 
an increased rate of oxidation of ascorbic acid to dehydroascorbic 
acid which, as has been shown, is a tissue process, or some 
inhibition of its further oxidation to dioxogulonic acid. An 
increased rate of interconversion of ascorbic acid and dehydro- 
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ascorbic acid need not necessarily affect the net loss by oxidation 
but it could affect it in either direction. 
The lower rate of excretion of oxalic acid found in 
rheumatoid arthritis patients is not due to diminished intake of 
ascorbic acid or to poor absorption of the vitamin since it is 
apparent even when rheumatoid arthritis patients are brought to 
"saturation" with ascorbic acid and also when the ascorbic acid 
is given by the intravenous route. This diminished urinary 
excretion of oxalate would therefore appear to indicate a difference 
in the metabolic pathway of ascorbic acid. It might be taken as 
evidence of a diminished net rate of oxidation of ascorbic acid 
but until more is known about the normal metabolic pathway of 
ascorbic acid in man this cannot be assumed. 
Damron, Monier and Roe (1952) did not consider that the 
reactions ascorbic acid-4 dehydroascorbic acid --j dioxogulonic 
acid represented the normal metabolic pathway in animal tissues. 
On the other hand the work of Curtin and King (1955) and Burns, 
Dayton and Schulenberg (1956), which has already been discussed, 
would appear to support the view that, in the guinea -pig and rat 
at least, the main pathway of metabolism of ascorbic acid is via 
dehydroascorbic acid to dioxogulonic acid and thence by oxidation 
of the entire carbon chain to carbon dioxide. Curtin and King 
found that when they injected "labelled" ascorbic acid, dehydro- 
ascorbic acid and dioxogulonic acid the proportion of the radio- 
activity found in the respiratory carbon dioxide and also in the 
urinary oxalate was least when ascorbic acid was injected and 
greatest when dioxogulonic acid was injected. It would appear 
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probable therefore that both the carbon dioxide and the oxalate 
arise after conversion to dioxogulonic acid but the experiments 
of Curtin and King and of Burns, Dayton and Schulenberg give no 
information as to whether prodution of oxalic acid is a necessary 
intermediate step in the conversion of dioxogulonic acid to carbon 
dioxide or whether it represents a divergent pathway. 
The results of Hellman and Burns (1955) who injected 
L- ascorbic -1 -C/4 acid into two human subjects are somewhat at 
variance with those obtained by Curtin and Kirg and - Burns, Dayton 
and Schulenberg with animals since they found that only 10., of 
the injected radio -activity appeared as respiratory C1402 and 
approximately 40¡ was excreted as oxalate. The difference might 
be due to a difference in the relation of the dose given to the 
biological requirement of the species. There are conflicting 
views as to human requirement for ascorbic acid but there is 
evidence that it may be extremely law; Bartley and his associates 
(1953) reported that 10 mg. ascorbic acid per day was sufficient 
to cure frank human scurvy completely while volunteers remained 
free from scurvy for over six months while receiving daily intakes 
which averaged less than 5 mg. 
Damron and his co- workers found that a small proportion only 
of the "total" ascorbic acid in all tissues was present as dehydro- 
ascorbic acid and dioxogulonic acid. It has long been considered 
probable that ascorbic acid functions as a hydrogen acceptor in 
some biological oxidation system but Meiklejohn (1953) has pointed 
out that it is dehydroascorbic acid which could function as a 
hydrogen acceptor and he has put forward the suggestion that the 
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ascorbic acid in the body tissues serves as a source of a small, 
but continuous, supply of dehydroascorbic acid. Neuberger (1949), 
in discussing the mechanism of the oxidation of tyrosine suggested 
that the oxidation of tyrosine or its keto -acids to homogentisic 
acid involves an attack by an electrophilic reagent. ';ieissberger 
and Lu Valle (1944), who studied the copper -catalysed auto -oxidation 
of ascorbic acid in vitro, concluded from their results that a 
monovalent ion is the substrate of the copper catalyst; regarding 
the monovalent ascorbate ion as the substrate they consider Cu + as 
an electron acceptor which can co- ordinate with the substrate before 
an electron shift takes place, giving an "ascorbic semiquinone ", 
which might perhaps be formulated as a free radicle. Cu+ which 
can co- ordinate less readily is released and oxidised by oxygen. 
Lloyd and Sinclair (1953) suggest that this semiquinone, which 
they take to be identical with the monodehydroascorbic acid of 
other writers, is the electrophilic (catanoid) reagent postulated 
by Neuberger (1949), in view of the evidence that ascorbic acid 
is necessary for the hydroxylation of p- hydroxy- phenylpyruvic 
acid to 2:5 dihydroxyphenylpyruvic acid. 
Definite chemical evidence for the existence of monodehydro- 
ascorbic acid has not been obtained; it is a hypothetical 
intermediate in a number of oxidations in which ascorbic acid 
appears to intervene in vitro and in vivo. Such a catanoid 
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Lloyd and Sinclair (1953) point out that it may be argued 
that the concentration of monodehydroascorbic acid will be 
proportional to the products of the concentrations of ascorbic 
acid and dehydroascorbic acid and that, for a given concentration 
of total ascorbic acid, the maximum concentration of monodehydro- 
ascorbic acid will be found at 500 oxidation to dehydroascorbic 
acid. The fact that it has been found that there is a tendency 
for rheumatoid arthritis patients to have a higher concentration of 
plasma dehydroascorbic acid than control subjects on the same 
ascorbic acid intake may, therefore, be an indication of an 
increased requirement for the production of monodehydroascorbic 
acid. If this be so it would be expected that this higher plasma 
concentration of dehydroascorbic acid would result in an increased 
rate of conversion to dioxogulonic acid and hence to an increased 
production of oxalic acid; yet Horne (1956) found that the tendency 
was for rheumatoid arthritis patients to excrete less oxalic acid 
than normal controls under the same dietary conditions and his 
findings have been confirmed in the present investigation. 
If it be postulated that there is increased production of 
53. 
monodehydroascorbic acid in response to an increased requirement 
for some biological oxidation process then the monodehydroascorbic 
acid, in acting as a hydrogen acceptor, will be re- converted to 
ascorbic acid. If at the same time there is in rheumatoid 
arthritis patients, as Iggo, Stewart and Thomson (1958) have 
shown, a more rapid passage of dehydroascorbic acid into the 
erythrocytes and reduction there to ascorbic acid it could be 
that this more rapid turnover of dehydroascorbic acid to ascorbic 
acid would result in a decreased tendency for dehydroascorbic acid 
to be converted to dioxogulonic acid and hence to a reduced 
production of oxalic acid. 
If, on the other hand, the maintenance of a higher concentration 
of dehydroascorbic acid - necessary to maintain an increased supply 
of monodehydroascorbic acid - results in an increased production 
of dioxogulonic acid and this in turn results in an increased 
production of oxalic acid the lower urinary excretion of oxalate 
in the rheumatoid patient must be due to a difference in the 
metabolism of oxalate. If the oxalate derived from ascorbic 
acid which is excreted in the urine represents an escape of 
oxalate from some tissue enzyme system then this tendency in 
rheumatoid arthritis to excrete less oxalate could be a result of 
increased tissue oxidation of oxalate to carbon dioxide. On the 
other hand, since at present there is not sufficient evidence to 
say whether dioxogulonic acid can be oxidised directly to carbon 
dioxide in the body without the intermediate formation of oxalic 
acid, this tendency to excrete less oxalic acid may be due to an 
increased rate of direct oxidation of dioxogulonic acid to carbon 
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dioxide in the rheumatoid condition. 
The role of ascorbic acid in tyrosine metabolism is the only 
part of the vitamin's activity in which the molecular processes that 
depend upon ascorbic acid are fairly clearly understood, although 
the work of Gould and Woessner (1957) is evidence of another possible 
role - in the hydroxylation of proline to hydroxyproline in collagen 
formation. It cannot be assumed that ascorbic acid may not be 
necessary for other metabolic processes within the animal organism 
and until more information is obtained regarding the functions and 
metabolic fate of ascorbic acid in man no clear explanation of the 
observed differences between rheumatoid arthritis patients and non - 
rheumatoid controls can be advanced. 
It would be of assistance in considering possible explanations 
of the tendency of rheumatoid arthritis patients to excrete less 
oxalate in the urine if it were known whether there is any difference 
between rheumatoid arthritis patients and non- rheuunatoid controls 
in the proportion of ascorbic acid, dehydroascorbic acid and 
dioxogulonic acid converted to respiratory carbon dioxide when 
each of these substances is injected. This data could best be 
obtained by experiments using ascorbic acid "labelled" with radio- 
active carbon - experiments outwith the scope of the present 
investigation. 4ithout such information all that can be stated 
definitely is that the results obtained support the view that the 
apparent deficiency of ascorbic acid which has been observed in 
rheumatoid arthritis patients is due to an alteration in the 
metabolism of the vitamin and is not due simply to a difference 
in intake, absorption, excretion or storage of ascorbic acid. 
55. 
Schroeder (1935), Harde et al (1935), Bullowa and co- workers 
(1936) and other workers have shown that a deficiency state with 
regard to ascorbic acid exists in a number of infectious conditions. 
The question arises therefore as to whether the apparent alteration 
in the metabolism of ascorbic acid is due directly to the rheumatoid 
arthritis disease process or whether it is a non -specific response 
to an inflammatory condition. Roe, Kuether and Zimler (1947) 
determined the levels of total ascorbic acid in the plasma and 
whole blood of 50 patients with various infectious conditions and 
found that in every case the concentration of total ascorbic acid 
was lower in the plasma than in whole blood; the concentration in 
the erythrocytes must therefore have been greater than in the plasma 
in each case. On the other hand Iggo et al (1958) found that 
although the erythrocytes of patients suffering from tuberculosis 
tended to reduce dehydroascorbic acid to ascorbic acid at a slightly 
more rapid rate than did the erythrocytes of control subjects in only 
one tuberculosis patient was the reducing -power of the erythrocytes 
above the upper limit of the normal range. The erythrocytes from 
rheumatoid arthritis patients had a reducing -power for dehydroascorbic 
acid that was significantly higher than that of the erythrocytes 
from control subjects. 
There is no information available with regard to the urinary 
excretion of oxalate in infectious conditions. Further investigation 
is required to compare (1) plasma and erythrocyte levels of ascorbic 
acid on the same dietary intake of the vitamin, (2) the ability of 
the erythrocytes to reduce dehydroascorbic acid to ascorbic acid, 
and (3) the urinary excretion of oxalate under similar dietary 
56. 
conditions, in rheumatoid arthritis patients, patients with various 
infectious conditions and normal controls. One difficulty in 
making such a comparison would be to obtain satisfactory objective 
criteria to assess the degree of inflammation present. 
'ehe results of the experiments in which cortisone or salicylate 
was given are difficult to assess. There was a transitory rise in 
the urinary excretion of ascorbic acid which occurred after the 
commencement of dosage with either of the drugs; increases in the 
urinary excretion of ascorbic acid have been reported as a result 
of dosage with salicylate (Spitzer and Shapiro, 1948) and the 
effect observed could be a purely renal one. However, the two 
rheumatoid arthritis patients who were receiving a high ascorbic 
acid intake showed a marked rise in the plasma level of ascorbic 
acid also immediately after commencement of the drug and it is 
difficult to conceive an alteration in the excretory mechanism 
which could produce a rise in plasma concentration at the same time 
as an increase in urinary excretion. A more probable explanation 
is that the coincident rise in plasma concentration and increased 
urinary excretion of ascorbic acid is due to an action of the drug 
in causing the ascorbic acid to pass from storage in the body 
tissues to circulation in the blood. It would seem probable 
however that the two control subjects on whom this particular 
experiment was performed, and whose initial plasma ascorbic acid 
concentration was considerably higher, would have a store in the 
tissues at least as great as the rheumatoid arthritis subjects, 
yet the effect of the drugs on the plasma level and urinary 
excretion in these control subjects was much less marked. It 
57. 
could be, however, that the effect of cortisone or salicylate on 
the disease -process present in the rheumatoid arthritis patients 
was such as to correct the alteration in ascorbic acid metabolism 
and thus - perhaps by a reduction in the rate of oxidation - to 
have an "ascorbic acid sparing" effect, but there is as yet not 




(1) It has been confirmed that rheumatoid arthritis patients 
have a lower plasma level and a lower urinary excretion of ascorbic 
acid than non -rheumatoid controls receiving the same intake of 
ascorbic acid. 
(2) It has been shown that these patients require a longer 
time to reach saturation with the vitamin, on a standard daily dose, 
than control subjects. 
(3) It has been shown also that rheumatoid arthritis patients 
have a lower level of ascorbic acid in the leucocytes, a higher 
dehydroascorbic acid concentration in the plasma and a higher 
ascorbic acid concentration in the erythrocytes than do normal 
subjects on the same dietary intake. 
(4) Patients with rheumatoid arthritis excrete less oxalic 
acid than do non -rheumatoid controls and show a smaller increase 
in excretion of oxalic acid after a large intravenous dose of 
ascorbic acid. 
(5) The implication of these findings has been discussed 
and points requiring further investigation have been suggested. 
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APPLNI'DIX. 
In the Tables which follow, the following abbreviations 
are used: 
AA = ascorbic acid 
DHA = dehydroascorbic acid 
Trúi = ''total" ascorbic acid 
.scorbic acid + dehydroascorbic acid 
+ dioxo;-ulonic acid). 
Osi = oxalic acid., 
TABLE 8. 
Ascorbic acid Saturation Tests. 
Non- rheumatoid subjects 




Subject Iio. Number of days to 
reach saturation. 
(1) 7 (1) 5 
(2) 4 (2) 6 
(3) 3 (3) 7 
(4) 3 (4) 5 
(5) 7 (5) 4 
(6) 5 (6) 6 
(7) 4 (7) 5 
(8) 3 (8) 5 
(9) 2 (9) 8 
(lo) 3 (lo) 7 
(11) 4 (11) 8 
(12) 4 (12) ó 
(3) 5 (13) 5 
(11+) 5 (14) 3 
(15) 4 (15) 4 






Mean 4.3 days 
S.D. 1.4 
= 2.72 
= less than 0.05 
Mean 5.5 days 
S.D. 1.3 
TABLE 9. 
Lxcretion of Ascorbic Acid in 24 hour period after test dose (500 mg.) 
"Unsaturated" subjects. 
Non- rheumatoid subjects. 
No. mg. TAri per 24 hours 
Rheumatoid arthritis subjects. 
No. mg. Tti1i per 21+ hours. 
(1) 12 (1) 14 
(2) 6 (2) 12 
(3) 6 (3) 12 
(4) 6 (4) 6 
(5) 4 (5) 6 
(6) 7 (6) 7 
(7) 6 (7) 14 
(8) 9 (8) 10 
(9) 12 (9) 9 
(10) 64 (10) 3 
(11) 17 (11) 7 
(12) 32 (12) 2 
(13) 37 (13) 4 
(14) 3 (14) 2 
(15) 11 (15) 2 
(16) 8 (16) 13 
(17) 28 
Mean 15.8 mg. 
S.D. 13.8 
Mean 7.7 mg. 
6.13. 4.4 
"t" 2.24 
"p" = less than 0.05 
Table 9 (continued) 
B. "Saturated" subjects. 
ì:on- rheumatoid subjects Theumatoid arthritis subjects 
Lo. mg. T1JA oer 24 hours ï;o. mg. per 24 hours. 
(i) 374 (1) 306 
264 300 
32o 
(2) 323 (2) 405 
382 348 
(3) 379 430 
(4) 280 (3) 
(5) 307 428 
(6) 334 235 
(7) 373 (4) 256 
(8) 268 378 
312 332 
(5) 264 
Mean 327 mg. 274 

















Mean 302 mg. 
S.D. 59.5 
"t" 1.27 
"p" = greater than 0.05 
TABLE 10. 
Concentration of Total Ascorbic Acid in Plasma and Erythrocytes. 
Non- rheumatoid subjects. 
Ido. Plasma TAA 
mg. /100 ml. 
Erythrocyte 
TAA 
m g. /100 ml. 
Plasma TAIL Difference: 
Erythrocyte TAA 
- plasma TAA 
mg. /100 ml. 
RatioErythrocyte 
TAA 
(1) 0.06 0.20 0.33 0.14 
(2) 0.20 0.15 1.33 - 0.05 
(3) 0.32 0.37 0.86 0.05 
(1+) 0.58 0.54 1.07 - 0.04 
(5) 0.07 0.19 0.37 0.12 
(6) 0.13 0.30 0.1+3 0.17 
(7) 0.58 0.80 0.73 0.22 
(8) 0.39 0.45 0.67 0.15 
(9) 0.20 0.32 0.63 0.12 
(io) 0.27 0.1+.1 0.66 0.11 
(11) 0.12 0.20 0.60 0.08 
(12) 0.21 0.34 0.62 0.13 
Mean 0.25 Mean 0.36 Mean 0.69 
mg. /100 ml. mg. /100 ml. 
S.D. 0.17 S.D. 0.18 S.D. 0.29 
Lean 0.10 
mg. /100 ml. 
S.D. 0.08 
TABLE 11. 
Concentration of 1.scorbic acid and Total Ascorbic acid in Plasma 
and Erythrocytes. 
Rheumatoid arthritis subjects. 
ho. Plasma TAIL 
m 100 ml. g./ 
Lrythrocyte TAA 
m 100 ml. g. 
Plasma TI1A Difference: 
Erythrocyte TAP. 
- plasma TAA 
mg. /100 ml. 
patio Erythrocyte TAk 
(1) 0.17 0.54 0.32 0.37 
(2) 0.03 0.46 0.07 0.43 
(3) 0.08 0.23 0.35 0.15 
(4) 0.58 1.04 0.59 0.46 
(5) 0.32 0.42 0.76 0.10 
(6) 0.58 1.42 0.41 0.84 
(7) 0.52 0.87 0.60 0.35 
(8) o.33 0.43 0.77 0.10 
(9) 0.26 0.75 0.35 0.49 
(10) 0,38 0.90 0.42 0,52 
(11) 0.23 0.57 0.40 0.34 
(12) 0.20 0.44 0.45 0.24 
(13) 0,20 0.56 0.36 0.36 
(14) 0.16 0.65 0.25 0.49 
(15) 0.06 0.50 0.12 0.44 
(16) 0.19 0.40 0.48 0.21 
(17) 0.15 0.51 0.29 0.36 
(18) 0.04 0.21 0.19 0.17 
(19) 0,20 0.43 0.47 0,23 
(20) 0.13 0.28 0.46 0.15 
(21) 0.06 0.48 0.13 0.42 
(22) 0.05 0.22 0.23 0.17 
(23) 0.11 0.22 0.50 0.11 
Mean 0.22 Mean 0.54 IUIean 0.39 Lean 0.33 
mg. /100 ml. uig. /100 ml. mg. /100 ml. 
S.D. 0.17 3.D. 0.29 S.D. 0.18 S.D. 0.17 
"t" 0.50 t" 2.05 "t" 
= 3.75 "t" = 21.37 
"p" = greater than "p" = less than "p" = less than "p" = less than 
0,1 0,05 0.01 0.01 
Ascorbic Acid and Total 
TABLE 12. 
Ascorbic Acid Content of Plasma. 
A. 
No. 
Low ascorbic acid intake (50 mg. per day) . 
Plasma TAA 
mg. /100 ml. 
lira 
Non- rheumatoid subjects. 
Plasma AA 
mg. /100 ml. 
Ratio 
TAA 
(1) 0.98 1.08 0.93 
(2) 0.78 1.05 0.74 
(3) 1.03 1.07 0.96 
(4) 0.89 1.00 0.89 
0.45 0.74 0.61 
(6) 0.69 0.78 0.88 
(8 
0.50 0.70 0.71 
0.43 0.55 0.79 
Mean 0.81 
S.D. 0.12 
Rheumatoid arthritis subjects. 
(1) 0.22 0.26 0.85 
(2) 0.25 0.30 0.83 
(3) 0.12 0.32 0.38 
4 0.21 0.30 0.70 
(5 0.19 0.38 0.50 
(6) 0.28 0.33 0.85 
7)) 0.42 0.82 0.52 
(8) 0.43 0.58 0.74 
(9) 0.31 0.64 0.49 
(10) 0.27 0.52 0.52 
(11) 0.32 0.58 0.54 
Mean 0.63 
B. 
"tu 2.56 "pi, less than 0.05. 
High ascorbic acid intake (500 mg. per day). 
S.D. 0.17 
Non- rheumatoid subjects. 
(1) 0.91 1.05 0.86 
(2) 1.40 1.43 0.98 
(3) 1.89 1.90 0.99 
(4) 1.95 2.00 0.98 
Mean 0.95 
S.D. 0.06 
Rheumatoid arthritis subjects. 
(1) 0.43 0.58 0.74 
(2) 0.65 0.76 0.86 
(3) 0.22 0.48 0.47 
(4) 0.56 0.74 0.76 
(5) 0.24 0.30 0.80 
(6) 0.13 0.25 0.52 
0.55 0.63 0.87 
(8) 0.95 1.13 0.84 
vean 0.73 
S.D. 0.15 
"t" = 2.70 "p" = less than 0.05. 
TAME 13. 










(1) 0.59 0.70 0.84 
0.95 0.96 0.99 
L 
) 
0.70 0.73 0.96 
0.76 0.80 0.95 
(J) 1.07 1.10 0.97 
1.10 1.10 1.00 
(4) 0.99 1.01 0.98 
0.97 1.00 0.97 
Eheumatoid arthritis subjects. 
AA TAA 





(1) 0.36 0.42 0.86 
0.60 0.67 0.90 
(2) 0.84 0.90 0.93 
0.44 0.43 1.02 
(J) 0.98 1.04 0.94 
0.90 0.93 0.97 
(4) 1.22 1.42 0.86 
"t., = 1.44 
i,rean 0.93 
S.D. 0.05 
"p" = greater than 0.1 
TABLE 14. 
Total Ascorbic Acid Content of Leucocytes. 




Rheumatoid arthritis subjects. 
No. n. L l'YL"1 
nir../100 ml. 
(i) 2.1 
5.0 (2) 7.0 
(2) 17.6 (3) 8.5 
20.5 (4) 2.6 
(3) 14.0 (5) 9.0 
(4) 19.9 (6) 6.5 
(5) 8.0 (7) 2.7 
(6) 7.1 (8) 5.8 
(9) 10.0 
(10 ) 4.1 
(11) 6.4 
Mean 12.5 mg./100 ml. Mean 5.9 mg./100 ml. 
o.D. 6.3 6.L. 2.7 
t« 
= 2.80 
"p" = less than 0.05 
TABLE 15. 
Urinary excretion of total ascorbic acid and oxalic acid. 



















(1) 27 80.3 3719 86.4 6.1 o.47 
(2) 11 48.1 4478 97.3 49.2 18.05 
(3) 10 51.3 4070 146.9 95.6 19.88 
(4) 45 84.5 3611 98.8 14.3 2.36 
(5) 34 91.1 3109 108.4 17.3 1.24 
(6)a 27 83.9 2924 146.4 62.5 6.89 
(6)b 19 53.9 2926 95.3 41.4 4.51 
(7) 25 72.7 2020 87.8 15.1 1.64 
(8) 21 57.4 2606 70.1 12.7 2.04 
(9) 14 35.9 4078 76.6 40.7 8.52 
Lean 23 69.4 3354 - 35.5 6.56 
S.D. 12 16.6 76o - 7.03 
TABLE 16. 
Urinary Excretion of Ascorbic Acid and Oxalic Acid. 
Rheumatoid arthritis subjects. 
Before injection 
Ile. Urine Urine 
TAA OA 
mg/48 hours mg/48 hours 
After injection Increase 
Urine Urine in ail 
TAA GA mg /48 hours 






(1) 5 35.2 1150 55.6 20.4 1.01 
(2) 3 37.9 2817 35.7 - 2.2 no increase 
(3) 12 28.4 3373 22.5 - 5.9 no increase 
(4) 21 50.7 1709 65.1 14.4 0.26 
(5) 20 54.1 1906 105.3 51.2 3.29 
(6) 14 68.4 3439 94.0 25.6 3.19 
(7) 3 55.7 4341 42.0 -13.7 no increase 
(8) 10 52.0 3412 37.7 -14.3 no increase 
(9) 17 53.7 3436 39.5 35.8 4.4), 
(10) 15 30.3 3253 2.2.9 - 7.4 no increase 
(11) 15 66.1 2779 81.3 15.2 1.63 
Mean 13 48.4 2874 - 10.8 1.26 
S.D. 5.1 13.6 930 - 2.71 
3.04 3.10 0.77 - 2.29 2.43 
"p" less thm 0.01 less than greater than - less than less than 0.05 
0.01 0.10 0.05 
TABLE 17. 
Urinary Excretion of Oxalic Acid in T heumatoid :arthritis ;'atients after 
"Saturation" with Ascorbic Acid. 
T; o. Before injection After injection 
OA mg. /48 hours CA rng. /L18 hours 
(1) 50.4 40.4 
Increase in 
OA 
m ./48 hours. 
- 10.0 
(2) 74.3 82.6 8.3 
(3) 52.5 60.2 7.7 
(4) 40.3 46.6 6.3 
(5) 66.3 114.1 47.8 
(6) 34.7 111.3 9.6 
(7) 26.b 58.4 31.8 
(8) 38.7 24.3 14.4 
Ye a1 48.0 - 10.8 
3.D. 13.6 
Compared with ) 11.L /I = 2.59 Ift = 2.14 
"unsaturated" ) 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Effect of salicylate. Rheumatoid arthritis 
subject 11e. 6. 
Day Plasma TAA 
mg/100 ml. 
Erythrocyte TAA 
rag. /100 ml, 
Urine TAA. 
mg. /24 hours 

















9 1.1.1 1.10 465 
31 3 35 
33 162 
35 112 























500 mg. /day 








Effect of salicylate. 
TABLE 28. 
subject No. 7. Rheumatoid arthritis 
Day Plasma TAR Erythrocyte TÎ s Urine TA ,. Period. 
mg./ 100 ml. mg. /100 ml. mg. /24 hours. 
1 0.17 0.54 6 Ordinary 
3 1 Hospital 
5 4 diet 
7 5 




15 0.10 0.25 3 Ordinary 
17 12 hospital diet 
19 18 + 500 mg. /day 




29 1.30 1.54 409 Ordinary 
31 314 hospital diet 
33 291 
35 328 
+ 500 mg. /day 










50 0.80 1.10 Ordinary 
51 43 hospital diet 
53 15 + salicylate. 
55 16 
57 1.17 0.70 
Dy mistake, the patient was kept on salicylate, 80 grains per day, 
from day 29 to end of test period. 
TABLE 29. 
Effect of salicylate. Rheumatoid arthritis subject No. 
may Plasma TAA 
mg. /100 ml. 
Erythrocyte TAA 
mg. /100 ml. 
Urine T.L:i 
rng. /24 hours 
1 8 























































Effect of cortisone. Rheumatoid arthritis subject No. 
Day Plasma TAA Erythrocyte TAA 
mg. /100 ml. mg. /100 ml. 
Urine TAA 
mg./24 hours 



















31 1.03 1.34 525 
33 299 
35 489 





45 0.73 0.86 398 
47 408 
49 492 




















diet, 500 mg. /day 
ascorbic acid + 










Effect of cortisone. 'rheumatoid arthritis subject No. 
Dazr Plasma TAA 
mg. /100 ml. 
Erythrocyte TAA 
mg. /100 ml. 
Urine TIC 
mg. /24 hours 
































57 1.16 - 48 
59 11 
61 8 








+ 500 mg. /day 
ascorbic acid. 
Patient on anti- 
coagulant treatment 
for phlebitis - high 
ascorbic acid dosage 
continued. 
Hospital diet, 









Effect of cortisone. 
TABLE 32. 
subject No. 1l. Rheumatoid arthritis 
Day Plasma TAA Erythrocyte TAA Urine TAA Period 
mg. /100 ml. mg. /100 ml. mg. /24 hours 






7 1 diet 








21 45 + 500 mg. /day 











36 1.08 1.08 
240 
500 mg. /day 
ascorbic acid 
37 515 + cortisone. 
39 203 
41 425 
43 0.67 0.92 198 Ordinary 
45 308 hospital diet, 
47 180 4 500 mg. /day 
49 87 ascorbic acid. 
50 0.80 1.18 Ordinary 
51 56 hospital 
53 20 diet 
55 9 
57 0.40 0.45 
